WO2004067561A1 - AMYLOID-β(1-42)-OLIGOMERE, DERIVATE DAVON UND ANTIKÖRPER DAFÜR, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG - Google Patents
AMYLOID-β(1-42)-OLIGOMERE, DERIVATE DAVON UND ANTIKÖRPER DAFÜR, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG Download PDFInfo
- Publication number
- WO2004067561A1 WO2004067561A1 PCT/EP2004/000927 EP2004000927W WO2004067561A1 WO 2004067561 A1 WO2004067561 A1 WO 2004067561A1 EP 2004000927 W EP2004000927 W EP 2004000927W WO 2004067561 A1 WO2004067561 A1 WO 2004067561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligomer
- protein
- antibody
- derivative
- oligomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Definitions
- the present invention relates to neuromodulating oligomers of the amyloid ⁇ (1-42) protein, a specific method of preparation, with which the oligomers are obtainable in a reproducible and high yield, and the use of oligomers as diagnostics and therapeutics, to produce oligomer-specific antibodies and to find substances that can interact with the oligomers and their formation.
- the invention also relates in the same way to derivatives of the oligomers, in particular crosslinked oligomers and oligomers based on truncated forms of the amyloid ⁇ (1-42) protein thereof, their preparation and their use.
- Amyloid ⁇ (1-42) protein also referred to as A ⁇ (1-42)
- a ⁇ is a central component of insoluble extracellular deposits (senile or neuritic plaques) composed of proteins, lipids, carbohydrates and salts in the brains of Alzheimer's and Down syndrome patients (CL Masters et al PNAS 82, 4245-4249, 1985).
- This protein which tends to polymerize in an aqueous environment, can exist in very different molecular forms.
- the soluble forms of A ⁇ (1-42) have two distinct hypotheses about the molecular forms that are believed to be responsible for dementias such as Alzheimer's disease.
- a ⁇ (1-42) -protofibrils are postulated. These are still soluble, fibrillar, higher aggregated A ⁇ (1-42) forms with molecular weights in the range of 150-250 kDa (Arispe et al., PNAS 90, 567 (1993), Lashuel et al., Nature 418, 291 (2002)), which are said to cause an uncontrolled influx of calcium through the membranes of neuronal cells due to pore-forming properties.
- oligomeric A ⁇ (1-42) derivatives having molecular weights in the range of 15-30 kDa (M.P. Lambert et al., PNAS 95, 6448-6453 (1998)) are described. These also referred to as amyloid-derived, diffusible and dementia-contributing ligands (ADDL's for Amyloid Derived Dementing Ligands, see US-A 6,218,506 and WO 01/10900, or for Amyloid Derived Diffusive Ligands, see Lambert et al., Supra), non-fibrillar oligomers are found in
- a disadvantage of the described manufacturing instructions is that they give inhomogeneous oligomer preparations.
- a ⁇ (1-42) responsible for neuromodulation could not yet be reproducibly provided, let alone unambiguously identified.
- N-terminally truncated forms of the A ⁇ (1-42) protein has been mentioned in connection with Alzheimer's disease.
- N-terminal truncated forms were detected in the deposits of brains of deceased Alzheimer's patients in addition to the A ⁇ (1-42) (C. Masters et al., PNAS 82, 4245-4249 (1985)).
- certain proteases occurring in the brain such as neprilysin (NEP 24.11) or IDE (short for "insulin degrading enzymes" can degrade A ⁇ (1-42) (DJ Selkoe, Neuron 32, 177-180, ( 2001)).
- Antibodies directed against monomeric A ⁇ (1-42) protein and certain fragment thereof have already been described.
- WO 03/016466 and WO 03/016467 relate to monoclonal antibody 266 and analogs thereof which lack a particular glycosylation site in CDR2.
- humanized versions of it (Hu-266) are known. These publications also mention other monoclonal antibodies which, like the antibody, recognize 226 epitopes in the region of amino acids 13-28 of A ⁇ (1-42). These include the antibodies 4G8 (also mentioned in Lue et al. (1999), supra) and 1C2. Furthermore, in McLean et al. (1999), supra, who mentions monoclonal antibody 1E8, which is to recognize an epitope in the region of amino acids 18-22 of A ⁇ (1-42).
- the object of the present invention which is to provide the neuromodulatory and in particular neurone-damaging effect of A ⁇ (1-42) causative and in dementia diseases, such as Alzheimer's disease and Down's syndrome, increasingly occurring molecular forms, solves the invention by certain A ⁇ (1-42) oligomers obtainable in the form of homogeneous preparations with a specific process from monomeric A ⁇ (1-42) protein, as well as by certain derivatives of these oligomers, in particular cross-linked oligomers and oligomers based on truncated A ⁇ ( 1 -42) - forms.
- the preparation process makes it possible to convert poorly aqueous-soluble, peptide-synthetic A ⁇ (1-42) protein in high yield into defined soluble oligomers.
- the present invention therefore relates to the objects defined in the patent claims.
- the present invention relates to oligomers of the amyioid ⁇ (1-42) protein, wherein the oligomers in SDS gel electrophoresis have an apparent molecular weight of about 15 kDa, 20 kDa, 38 kDa or 48 kDa, or derivatives of the oligomers with an optionally modified derivatization according to the molecular weight.
- Amyloid ⁇ (1-42) protein represents a 42 amino acid polypeptide derived by proteolytic processing from amyloid precursor protein (APP).
- APP amyloid precursor protein
- Isoforms of the amyloid ⁇ (1-42) protein which are found in organisms other than humans, especially other mammals, especially rats.
- the present invention relates to oligomers of human amyloid ⁇ (1-42) proteins.
- Human amyloid ⁇ (1-42) proteins include, in particular, the protein having the amino acid sequence SEQ ID NO: 1, as well as muteins and allelic variants thereof, which are derived from said sequence, in particular by amino acid exchange.
- amino acid substitutions should be mentioned: A21G, E22K, E22Q, E22G and D23N.
- the muteins or allelic variants of the amyloid ⁇ (1-42) protein according to the invention include, in particular, proteins having an amino acid sequence SEQ ID NO: 1 in which one or more amino acids selected from alanine 21, glutamic acid 22 and aspartic acid 23 with a other, preferably selected from glycine, lysine, glutamine and asparagine, amino acid are substituted.
- amino acids selected from alanine 21, glutamic acid 22 and aspartic acid 23 with a other, preferably selected from glycine, lysine, glutamine and asparagine, amino acid are substituted.
- substitutions at position 22, in particular with glutamine or glycine are substitutions at position 22, in particular with glutamine or glycine.
- Rat amyloid ⁇ (1-42) proteins include, in particular, the protein having the amino acid sequence SEQ ID NO: 2, as well as muteins and allelic variants thereof, which are derived from said sequence, in particular by amino acid exchange.
- amino acid substitutions are to be mentioned, which correspond to the explained for the human sequence amino acid substitutions.
- Amyloid ⁇ (1-42) protein can be prepared by known peptide synthetic methods or recombinantly. In addition, a number of these proteins are commercially available. The same applies to muteins and allelic variants.
- the oligomers of the invention are obtainable by oligomerization of amyloid ⁇ (1-42) protein.
- the oligomerization involves non-covalent aggregation of monomeric amyloid protein, so it can be understood that the oligomers of the present invention are composed of multiple amyloid ⁇ (1-42) protein monomers.
- the oligomers according to the invention have different molecular weights.
- apparent molecular weights can be assigned to the oligomers. These are about 15 kDa for the oligomer A1, about 20 kDa for the oligomer A2, about 38 kDa for the oligomer B1 and about 48 kDa for the oligomer B2, when the gel electrophoresis under standard denaturing conditions (Tris-glycine gel, 4-20%, see Lämmli UK, Nature 227, 680-685 (1970)), wherein the following standard proteins have the same apparent molecular weights under the same conditions: myosin 250 kDa, bovine serum albumin 98 kDa, glutamine hydrogenase 64 kDa, carboanhydrase 36 kDa, myoglobin 30 kDa, lysozyme 16 kDa
- the molecular weights for the oligomers B are about 64 to 90 kDa when subjected to gel electrophoresis under standard native conditions (Tris-glycine gel, 4-20%), the following standard proteins having the same apparent molecular weights under the same conditions: myosin 250 kDa, bovine serum albumin 98 kDa, glutamine hydrogenase 64 kDa, carboanhydrase 36 kDa, myoglobin 30 kDa, lysozyme 16 kDa, aprotinin 6 kDa, insulin B chain 4 kDa (see Blue Pre-stained Standard).
- the oligomers of the invention are characterized by an affinity for neuronal cells. It is expected that the oligomers will bind to certain cell surface proteins, particularly receptors.
- the present invention also relates to a method for determining the binding of an oligomer according to the invention to a predetermined cellular structure, wherein i) the oligomer according to the invention is allowed to act on the cellular structure and ii) determines whether the oligomer according to the invention binds to the cellular structure.
- the oligomers of the invention are characterized by a neuromodulating effect.
- This neuromodulating effect can manifest itself in particular in a reduced survival capacity of neuronal cells, for example neuroblastoma cells (neurotoxicity), if at least one oligomer according to the invention is allowed to act on a culture of these cells.
- the viability of the cells can be assessed in a manner known per se, for example by determining the extent of apoptosis caused by the action of the oligomers according to the invention. Suitable test methods, for example colorimetric methods based on 3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide (MTT), are available for this purpose.
- the present invention also relates to a method for determining the activity, in particular the neurotoxicity, of an oligomer according to the invention, wherein i) the oligomer according to the invention is allowed to act on cells and ii) determines whether the state of the cells changes.
- oligomer according to the invention in the manner described above, e.g. in the form of one of the above-mentioned compositions.
- the cells or cellular structures are expediently in vitro, in particular as cell culture or in cellular
- Neuronal cells and in particular neuroblastoma cells serve to determine neurotoxicity.
- the cells may also be in vivo, especially as part of an organism, e.g. an experimental animal, or ex vivo.
- the condition of the cells is usually determined at least once before and at least once after exposure to the oligomer. If a comparison between the state before and the state after the action indicates a deviation, the tested oligomer has activity.
- the type of condition to be determined depends on the type of activity to be determined.
- Neurotoxicity can be determined by, for example, determining the survivability. For this purpose one can determine the proportion of living cells based on the total cell number before and after the action of the oligomer and compare with each other.
- the method is carried out at least twice, once in the presence of the test substance and once again without test substance.
- the test substance is added to the oligomers usually after their provision.
- the substance is expediently added even before the formation of the oligomers, ie even before their preparation, for example the educt (s) used for the oligomer formation.
- the preparation process of the invention with the addition of the test substance and then determine whether and to what extent the oligomers are formed.
- the oligomers B of the invention are to be preferred. Derivatives of these oligomers are also preferred in this regard, with particular emphasis on the oligomers based on an N-terminally shortened A ⁇ (1-42) protein.
- the oligomers A and the oligomers B may be obtained as a mixture in the form of compositions which, in addition to the oligomers further small amounts of other polypeptides, in particular monomeric amyloid ß (1-42) protein and optionally also higher molecular forms aggregated amyloid - ⁇ (1-42) protein.
- Such compositions are likewise provided by the present invention and are distinguished in particular by the fact that the proportion of oligomer (s) according to the invention relative to the totality of the proteins derived from the amyloid ⁇ (1-42) protein is at least 70% by weight .-%, preferably at least 90 wt .-% and in particular at least 95 wt .-% is.
- the proportion of the oligomer A2 (20 kDa band in the SDS gel) is at least 50% by weight and preferably at least 70% by weight and in particular at least 85% by weight.
- the proportion of the oligomers B1 and B2 (38 kDa and 48 kDa bands in the SDS gel) is at least 60 wt .-%, preferably at least 75 wt .-% and in particular at least 90 wt .-%.
- the oligomers of the invention may also be derivatized.
- the purpose of such derivatizations may be, for example, to modulate the physicochemical properties of the oligomers, in particular with regard to bioavailability, to provide the oligomers with a detectable label or to immobilize, for example, to be coupled to the carrier. Labeling and immobilization are particularly important for diagnostic applications. Suitable markers well known in the protein biochemical field are well known to the person skilled in the art. These include fluorescence labels, for example certain fluorescein and tetramethylrhodamine derivatives, luminescent labels, colorimetric labels, radioactive labels and magnetic labels, and labels with affinity for complementary binding partners, such as biotin and streptavidin derivatives.
- the oligomer derivatives have molecular weights which may be correspondingly increased in comparison to the underivatized oligomers, the
- aggregation number is the same.
- a biotin derivative based on the A ⁇ (1-42) oligomer B1 having a molecular weight in the 38 kDa SDS gel has a molecular weight of 42 kDa.
- the oligomers are crosslinked.
- Suitable cross-linking agents are known to those skilled in the art and are typically bifunctional reagents such as formaldehyde, glutaric dialdehyde, disuccinimidyl suberate, dithiobis (succinimidylpropionate), disuccinimidyl tartrate, disulfosuccinimidyl tartrate, dimethyl adipimidate, dimethyl pimelidate, dimethyl suberimidate, dimethyl 3,3'-dithiobispropionimidate, N- ⁇ - maleinimidobutyloxysuccinimide ester, succinimidyl-4 (N-maleimidomethyl) cyclohexane-1-carboxylate, N-succinimidyl- (4-iodoacetyl) aminobenzoate and N-succinimidyl-3- (2-pyridyldithio) propionate.
- Such cross-linked oligomers have the advantage that they are stabilized and their oligomerization is generally no longer reversible. They are therefore particularly suitable for use in diagnostic test systems or as an immunogen for the production of oligomer-specific antibodies.
- the derivatives of oligomers according to the invention also include oligomers of
- Fragments of amyloid ⁇ (1-42) protein Preferred are those fragments obtainable by the action of naturally occurring proteases.
- the fragments obtainable by proteolysis under non-denaturing conditions in physiological buffers have increased proteolytic stability compared to the amyloid ⁇ (1-42) protein.
- the fragments are obtainable by the action of trypsin, chymotrypsin, thermolysin, elastase, papain or endoproteinase GluC.
- those fragments are preferred whose oligomers according to the invention are replaced by a neuromodulating Effect are marked. To further explain this aspect, reference is made to the corresponding discussion of the neuromodulating effect of oligomers of the amyloid ⁇ (1-42) protein of the invention.
- preferred fragments are characterized in particular by being derived from the amyloid ⁇ (1-42) protein by cleavage of N-terminal sequences.
- these N-terminal sequences may be fragments of up to 23, preferably up to 21, and most preferably up to 19 amino acids of the N-terminal sequence of the amyloid ⁇ (1-42) protein.
- preference is given to fragments of the A ⁇ (1-42) protein whose sequence comprises amino acids 24 to 42, preferably 22 to 42 and in particular 20 to 42 in continuous sequence.
- the N-terminal sequences to be cleaved may be sequences having at least 7, preferably at least 9, and most preferably at least 11 amino acids of the N-terminal sequence of the amyloid ⁇ (1-42) protein.
- fragments of the amyloid ⁇ (1-42) protein are preferred, which are shortened N-terminally by 7 to 23, preferably 9 to 21 and in particular 11 to 19 amino acids.
- These fragments correspond to the formula A ⁇ (x-42), where x is 8 to 24, preferably 10 to 22 and especially 12 to 20.
- fragments from the following fragments: A ⁇ (8-42), A ⁇ (9-42), A ⁇ (10-42), A ⁇ (11-42), A ⁇ (12-42), A ⁇ (13-42), A ⁇ (14-42), A ⁇ (15-42), A ⁇ (16-42), A ⁇ (17-42), A ⁇ (18-42), A ⁇ (19-42), A ⁇ (20-42), A ⁇ (21-42), A ⁇ (22-42), A ⁇ (23-42) and A ⁇ (24-42).
- Specific fragments are the amyloid ⁇ (20-42) fragment obtainable by the action of thermolysin and the amyloid ⁇ (12-42) fragment obtainable by the action of endoproteinase GluC.
- Derivatives of the invention also include those derived from an amyloid ⁇ (1-42) protein having C-terminal 1 or 2 further amino acids.
- oligomers of the A ⁇ (1-43) protein or the above include corresponding derivatives thereof.
- the process according to the invention for the preparation of the oligomers may comprise essentially three steps, of which the first step is optional but advantageous, the second step for the preparation of the oligomers A and B is mandatory and the third step is the preparation of the oligomers B according to the invention.
- Step 1 concerns the unfolding of the protein.
- hydrogen bond-breaking agents such as hexafluoroisopropanol (HFIP)
- HFIP hexafluoroisopropanol
- DMSO Dimethylsulfoxide
- the protein can be taken up in a slightly acidic, preferably aqueous, solution, for example an approximately 10 mM aqueous HCl solution. After an incubation period of generally a few minutes, insoluble constituents are centrifuged off. A few minutes at 10,000 g are appropriate.
- These process steps are preferably carried out at room temperature, i. a temperature in the range of 20 to 30 ° C performed.
- the supernatant obtained after centrifugation contains the amyloid ⁇ (1-42) protein and can be temporarily stored at low temperature, for example at about -20 ° C.
- Step 2 relates to the oligomerization of the protein to the oligomers A.
- a detergent is allowed to act on the optionally at least partially unfolded protein until sufficient oligomer A is formed.
- ionic detergents in particular anionic detergents.
- a detergent is used
- RX wherein the radical R is optionally branched alkyl having 6 to 20 and preferably 10 to 14 carbon atoms or optionally branched alkenyl having 6 to 20 and preferably 10 to 14 carbon atoms, the radical X is an acidic group or their Salt, where X is preferably selected from -COO ' M + , -SO 3 ' M + and especially
- Alkaline earth metal cations and ammonium cations selected inorganic or organic cation are advantageous, of which in particular alk-1-yl radicals may be mentioned. Particularly preferred is sodium dodecyl sulfate (SDS). Also lauric acid and oleic acid can be used advantageously. Also the sodium salt of the detergent lauroylsarcosine (also known as sarkosyl NL-30 or Gardol ® known) is particularly advantageous.
- the exposure time of the detergent depends on whether - and if so, to what extent - the protein introduced into the oligomerization is unfolded.
- a hydrogen bond-breaking agent ie in particular with hexafluoroisopropanol, rich
- Exposure times in the range of a few hours advantageously about 1 to 20 and in particular about 2 to 10 hours then when the exposure temperature is about 20 to 50 ° C and in particular about 35 to 40 ° C. If less or essentially unfolded protein is assumed, correspondingly longer exposure times are expedient.
- the amyloid ⁇ (1-42) protein has been pretreated according to the procedure outlined above as an alternative to step 1, or if it is entered directly in step 2, exposure times will range from about 5 to 30 hours and more preferably from about 10 to 20 hours then when the exposure temperature is about 20 to 50 ° C and especially about 35 to 40 ° C. After incubation, insoluble constituents are advantageously centrifuged off. A few minutes at 10,000 g are appropriate.
- the selected detergent concentration depends on the detergent used. When SDS is used, a concentration in the range of 0.01 to 1% by weight, preferably 0.05 to 0.5% by weight, for example, about 0.2% by weight, proves useful. If lauric acid or oleic acid are used, somewhat higher concentrations are expedient, for example in a range from 0.05 to 2% by weight, preferably from 0.1 to 0.5% by weight, for example from about 0.5% by weight. %.
- the action of the detergent should be at a salt concentration approximately in the physiological range.
- NaCl concentration in the range of 50 to 500 mM, preferably from 100 to 200 mM and especially at about 140 mM are useful.
- the resulting, the oligomers A ie in particular the oligomers A1 and / or A2 containing solution can be temporarily stored at low temperature, for example at about -20 ° C.
- it can be fed to the oligomers B according to the invention or the further reaction, or further work-up or purification steps can initially follow, with which, in particular, a further enrichment of at least one the oligomers A of the invention is achieved.
- affinity chromatographic methods are suitable for this purpose, in which, for example, specific antibodies, ie in particular also the oligomer-specific antibodies according to the invention, can be used.
- Step 3 relates to the oligomerization to the oligomers B.
- a composition containing oligomer A is selected as starting material for this step.
- the oligomers A have meaning according to the invention as intermediates for the preparation of the oligomers B. If this composition comes from step 2, it regularly contains detergent and a salt concentration in the physiological range. Then it is appropriate to reduce the detergent effect or the salt concentration. This can be achieved by reducing the detergent or salt concentration, e.g. by dilution, conveniently with water or a buffer of lower salt concentration, eg. B. Tris-HCl, pH 7.3, take place.
- Dilution factors in the range of about 2 to 10, advantageously in the range of about 3 to 8 and in particular of about 4 have been found to be suitable.
- the reduction of detergency can also be achieved by the addition of substances which can neutralize detergency.
- substances capable of complexing the detergents such as substances capable of stabilizing cells in the course of purification and extraction procedures, e.g. certain EO / PO block copolymers, in particular the block copolymer guided under the trade name Pluronic® F 68.
- alkoxylated and in particular ethoxylated alkylphenols such as the ethoxylated t-octylphenols of the Triton® X series, in particular Triton® X100, 3- (3-cholamidopropyl-dimethylammonio) -1-propanesulfonate (CHAPS®) or alkoxylated and in particular ethoxylated sorbitan fatty acid esters such as those of the Tween® series, in particular Tween® 20, in concentration ranges in the range or above the respective critical micelle concentration.
- ethoxylated alkylphenols such as the ethoxylated t-octylphenols of the Triton® X series, in particular Triton® X100, 3- (3-cholamidopropyl-dimethylammonio) -1-propanesulfonate (CHAPS®) or alkoxylated and in particular ethoxylated sorbitan
- the solution is incubated until sufficient oligomer B has formed. Exposure times in the range of several hours, preferably in the range of about 10 to 30 hours and in particular in the range of about 15 to 25 hours are sufficient if the exposure temperature about 20 to 50 ° C and in particular about 35 to 40 ° C. Then you can concentrate the solution and spin off any residues. Again, prove to be a few minutes at 10,000 g as appropriate. The supernatant obtained after centrifugation contains oligomers B.
- the oligomers B i.
- the oligomers B1 and / or B2 containing solution can be stored in the meantime at low temperature, for example at about -80 ° C. It can be supplied as such to the use of the invention or it may initially further Aufarbeitungsl. Connect cleaning steps. In this regard, reference is made to the above statements on corresponding measures in connection with the oligomers A.
- the oligomers B may first be precipitated from the detergent-containing solution, recovered and redissolved in detergent-free medium. Measures for precipitation of proteins are well known to those skilled in the art. According to the invention, the addition of aqueous methanolic acetic acid has proven to be expedient. Without being bound by any particular mechanism, the detergent or salt variation of detergent and salt concentrations appears to be the most important
- Subunits are able to decompose, whereas according to the invention, starting from a monomer tending to aggregate defined oligomers are obtained.
- the crosslinking of oligomers according to the invention or derivatives thereof can be carried out in a manner known per se. If, for example, glutaric dialdehyde is used as the crosslinking agent, one from process step 2 according to the invention can be used or 3 resulting solution with a glutaric dialdehyde solution. After a few hours at room temperature, the oligomers reacted with the glutaraldehyde. The reaction can then be stopped in a manner known per se by reacting the excess glutaric dialdehyde with reagents generally known for this purpose, such as ethanolamine. Depending on whether the oligomers A or B according to the invention are cross-linked, a solution of crosslinked oligomers according to the invention which are denoted by A-CL or B-CL is obtained.
- the optionally cross-linked oligomers B or derivatives thereof it is possible, following their synthesis, to increase the salt concentration again without impairing the stability of the oligomers. This is important in view of the use of the oligomers, e.g. in the case that in use physiological conditions are appropriate (cellular applications, in vivo applications).
- oligomers of fragments of the amyloid ⁇ (1-42) protein can be prepared by proteolysis, either starting from corresponding monomer fragments by oligomerization or starting from oligomers of the amyloid ⁇ (1-42) protein.
- a solution resulting from the process steps 2 or 3 according to the invention can be treated with protease.
- the protease is inactivated in a generally known manner.
- the resulting oligomers can then be obtained based on procedures already described herein and, if necessary, by further Aufarbeitungsc. Cleaning steps are further processed.
- novel oligomers and the compositions containing them are characterized by their homogeneity and stability. They are soluble in physiological media, eg, physiological saline, and differ from fibrillar forms in their more globular appearance. They have the advantage of having a spatial structure that clearly differs from other A ⁇ (1-42) forms, especially the monomer, non-toxic oligomers, the A ⁇ (1-42) precursor molecule APP, protofibrils and fibrils. They are therefore particularly suitable for the generation of specific antibodies both in vivo and in vitro and allow, for example, a specific active immunization. It may be crucial to use for immunization only those oligomers that are responsible for the disease.
- a ⁇ (1-42)
- the monomeric molecule or smaller oligomers may be necessary for important signaling functions in the organism be.
- the removal of the fibrillar deposits, which are believed to be important for the lining of the cells, can damage the organism.
- homogeneous oligomers and compositions containing them therapeutic options, such as passive immunization, the use of destabilizers of the oligomeric forms and the use of receptor (partial) agonists or antagonists.
- a homogeneous oligomer preparation also allows a targeted production of polyclonal or monoclonal antibodies for passive immunization.
- the discovery of disease-relevant receptor molecules or signal molecules which are influenced by this oligomeric form is also possible with the oligomers according to the invention and compositions containing them.
- oligomers of the invention possess diagnostic and therapeutic value due to their involvement in amyloid ⁇ ⁇ protein-associated physiological processes.
- the use of oligomers according to the invention and derivatives thereof, optionally in the form of a corresponding composition, in diagnostic in vitro and in vivo detection methods is the subject of the present invention.
- Amyloid ⁇ -protein-associated physiological processes include those associated with deposition of amyloid proteins (amyloidoses). These include both those processes that lead to structural changes of nerve tissue and are important, for example, in Alzheimer's disease and Down's syndrome, as well as those processes that affect other tissues, such as amyloid microangiopathies, such as Congophilic amyloid angiopathy (CAA ).
- amyloidoses include those associated with deposition of amyloid proteins (amyloidoses). These include both those processes that lead to structural changes of nerve tissue and are important, for example, in Alzheimer's disease and Down's syndrome, as well as those processes that affect other tissues, such as amyloid microangiopathies, such as Congophilic amyloid angiopathy (CAA ).
- CAA Congophilic amyloid angiopathy
- Another object of the present invention is the use of oligomers according to the invention and derivatives thereof, optionally in the form of a corresponding composition, for the production of oligomer-specific antibodies.
- the oligomers according to the invention based on truncated forms of the A ⁇ (1-42) protein are of particular importance: because of the lacking N-terminus, they can be used to generate a significantly more selective immune response than with the A ⁇ (1-42) protein. While the highly immunogenic N-terminus in classical A ⁇ (1-42) protein predominantly results in antibodies specific for this region of the molecule, eg the antibodies 6E10 (F.
- Immune response may also result in fewer side effects (e.g., brain hemorrhage, impairment of the physiological neurotrophic activity of the in situ monomeric form). Also, for passive immunization, i. an antibody therapy, especially monoclonal antibodies produce and select better.
- One aspect of this use is the generation of oligomer-specific antibodies as part of a therapy.
- a further object of the present invention is the use of an oligomer or derivative thereof according to the invention in the therapeutic field, in particular as a vaccine.
- Such a vaccine is usually a pharmaceutical composition containing at least one oligomer according to the invention and / or at least one derivative thereof according to the invention.
- a pharmaceutical composition containing at least one oligomer according to the invention and / or at least one derivative thereof according to the invention.
- one of the inventive, two or more oligomer-containing compositions, or a combination of different compositions can be used.
- the composition may contain a physiologically acceptable carrier and optionally other excipients, for example immunostimulants.
- the vaccines according to the invention can be formulated in particular in a form suitable for parenteral, for example intravenous, intramuscular and subcutaneous administration.
- the carrier preferably contains water, saline, alcohol, a fat, a wax and / or a buffer.
- an adjuvant may be included.
- Most adjuvants contain a substance intended to protect the antigen from rapid catabolism, such as aluminum hydroxide or a mineral oil, as well as lipid A, Bortadella pertussis or Mycobacterium tuberculosis-derived protein.
- Suitable adjuvants are usually commercially available, for example complete or incomplete Freund's adjuvant; AS-2; Aluminum salts such as aluminum hydroxide (optionally gel) or aluminum phosphate; Calcium, iron or zinc salts; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; Monophosphoryl lipid A. Cytokines such as GM-CSF or interleukin-2, -7 or -12 may also be used as adjuvants.
- the present invention relates to a process for the preparation of
- Antibodies comprising: i) immunizing a host with at least one oligomer of the invention, derivative thereof or composition; and ii) recovering an antibody-containing serum of the host formed in response to the immunization.
- immunization cocktails containing mixtures of different oligomers or oligomer derivatives according to the invention are administered for immunization.
- the oligomers or oligomer derivatives to be used are not or only weakly immunogenic, their immunogenicity can be increased by adding them to carriers, preferably a carrier protein, such as keyhole limpet hemocyanin (KLH), limulus polyphenus hemocyanin ((LPH),
- KLH keyhole limpet hemocyanin
- LPH limulus polyphenus hemocyanin
- a number of coupling possibilities are known to those skilled in the art, which are well known, for example, the reaction with glutaric dialdehyde, for example by incubation of the oligomer or oligomer mixture with a suitable peptide or peptide mixture in water or an aqueous solvent.
- This reaction may conveniently be carried out at ambient temperature, usually room temperature, but it may also be convenient to cool or slightly heat it, usually within a few hours to the desired result, a reaction time of, for example 2 h is in the usual range.
- the glutaraldehyde concentration is usually in the ppm to% range, suitably from 10 ppm to 1%, preferably from 100 ppm to 0.5%.
- the optimization of the reaction parameters is within the skill of the art and should take into account that the Oligomers A and B or oligomer derivatives are stable under the selected reaction conditions.
- the components to be used are first combined. It is advantageous to first incubate the resulting component mixture. This is conveniently done at ambient temperature, usually at room temperature. However, it may be convenient to cool or slightly heat the mixture. The incubation period is usually a few minutes to a few hours, an incubation period of 1 h has proved to be advantageous.
- immunization cocktails will generally contain other adjuvants, especially adjuvants commonly used for immunization, e.g. Freund's adjuvant.
- adjuvants commonly used for immunization e.g. Freund's adjuvant.
- complete Freund's adjuvant is used for the first immunization whereas all further immunizations are performed with incomplete Freund's adjuvant.
- the antigen preferably as a component mixture described above, is added to the excipient (s). As a rule, the antigen is emulsified.
- Rodents or even rabbits are particularly suitable as hosts. These or other suitable hosts are injected with the immunization cocktails, preferably subcutaneously.
- the antibody titers can be determined by an immunoassay, for example, competitive with a sheep anti-host IgG and labeled oligomer.
- a particular host is suitable for antibody production. For example, if four immunizations are performed, one can determine the antibody titer after the third immunization and then obtain antibodies from animals that have sufficient antibody titer.
- At least one antibody of the serum which used it as the immunogen is selected Oligomer, a derivative thereof or at least one contained in the composition used as the immunogen oligomer or derivative thereof specifically recognizes.
- Specificity in this context means a higher binding affinity of the antibody for the immunogen than for other, in particular related, proteins, in particular in comparison to monomeric amyloid ⁇ (1-42) protein and oligomeric or multimeric amyloid ⁇ (1-42). Protein aggregates having a higher molecular weight than the oligomers of the invention.
- Monoclonal oligomer-specific antibodies can also be obtained in this way. For this purpose, however, it is preferred to remove spleen tissue from the hosts and, starting from the spleen lymphocytes thus obtained, to establish hybridomas which produce the monoclonal antibodies in the usual way.
- B lymphocytes Part of a mammalian immune system is B lymphocytes, which as a whole contain an antibody repertoire composed of hundreds of millions of different antibody specificities.
- a normal immune response against a particular antigen means the selection of one or more antigen-specifically binding antibodies from that repertoire, and the success of an immune response is based, at least in part, on the ability of those antibodies to specifically recognize (and eventually eliminate) the stimulatory antigen. while ignoring other molecules from the environment of the antibodies.
- the antigen of interest may be allowed to act on the antibody repertoire either in vivo or in vitro.
- the antigen is allowed to act on the repertoire by immunizing an animal with the antigen in vivo.
- This in vivo approach may further involve establishing a series of hybridomas from the lymphocytes of an animal and selecting a hybridoma which secretes an antibody specifically binding the antigen.
- the animal to be immunized may be, for example, a mouse, rat, rabbit, chicken, camelid or sheep or a transgenic version of any of the aforementioned animals, for example, a human immunoglobulin gene transgenic mouse that makes human antibodies to an antigenic stimulus.
- mice with severe combined immunodeficiency that have been reconstituted with human peripheral blood mononuclear cells (chimeric hu-PBMC-SCID mice) or with lymphoid cells or progenitors thereof, as well as Mice treated with lethal whole body irradiation, then protected against radiation with bone marrow cells from a mouse with severe combined immunodeficiency (SCID) and subsequently transplanted with functional human lymphocytes (the so-called Trimera system).
- SCID severe combined immunodeficiency
- Another type of animal to be immunized is an animal (eg, a mouse) in the genome of which an endogenous gene encoding the antigen of interest has been knocked out, eg, by homologous recombination, such that this animal is immunized with
- an animal eg, a mouse
- an endogenous gene encoding the antigen of interest has been knocked out, eg, by homologous recombination, such that this animal is immunized with
- the antigen is allowed to act on the antibody repertoire in vitro by screening a recombinant antibody library with the antigen.
- the recombinant antibody library may be expressed on the surface of bacteriophages or on the surface of yeast cells or on the surface of bacterial cells.
- Embodiments is the recombinant antibody library, for example an scFv bank or a Fab bank.
- antibody libraries are expressed as RNA-protein fusions.
- the antigen can be allowed to act on the antibody repertoire by immunizing an animal with the antigen in vivo, and then recombinant antibody library or single domain antibody library (eg, heavy and / or light chain) prepared from lymphoid cells of the animal Antigen screent in vitro.
- the antigen is allowed to act on the antibody repertoire by immunizing an animal with the antigen in vivo and then affinity maturing a recombinant antibody library or single domain library prepared from lymphoid cells of the animal.
- the antigen is allowed to act on the antibody repertoire by immunizing an animal with the antigen in vivo, then selecting individual antibody-producing cells which secrete an antibody of interest and recovering from these selected cells cDNAs for the heavy and light chain variable region (eg by PCR) and the heavy and light variable regions Chain is expressed in vitro in mammalian host cells (referred to as the lymphocyte antibody selection method, or SLAM for "Selected Lymphocyte Antibody Method"), allowing further selection and manipulation of the selected antibody gene sequences, and monoclonal antibodies can be selected by expression cloning be expressed by expressing the antibody genes for the heavy and light chain in mammalian cells and selecting those mammalian cells which secrete an antibody with the desired binding affinity.
- the lymphocyte antibody selection method referred to as the lymphocyte antibody selection method, or SLAM for "Selected Lymphocyte Antibody Method
- those polyclonal and monoclonal antibodies can be selected which bind an oligomer or derivative thereof, but not other forms of the A (1-42) protein, APP, amyloid fibrils or amyloid plaques and a number of other unrelated antigens and tissues ,
- the person skilled in the art is well aware that antibody selections are based on well-defined antigens. However, if less well-defined antigens are used, they are not selective enough. In short, in vitro exposure and selection are similar to affinity chromatography, separating "ligands" for the desired antigen from those that do not bind the antigen with sufficient affinity, thus the level of enrichment of the desired antibodies from the vast pool of other antibodies is a direct consequence
- the oligomers and derivatives thereof according to the invention are antigens with which suitable, relevant and selective antibodies accumulate and antibodies recognizing other forms associated with the A (1-42) protein and other unrelated antigens , effectively disconnect.
- antibodies different types of antibodies can be produced. These include, but are not limited to, human antibodies, chimeric antibodies, humanized antibodies and CDR graft antibodies, and antigen-binding portions thereof.
- methods for producing antibodies according to the invention are described. A distinction is made between in vivo approaches, in vitro approaches, or a combination of both.
- monoclonal antibodies can be isolated by standard techniques such as those originally described by Kohler and Milstein (1975, Nature 256: 495-497) (see also Brown et al., (1981) J. Immunol 127: 539 Brown et al (1980) J. Biol Chem 255: 4980-83; Yeh et al. (1976) PNAS 76: 2927-31; and Yeh et al. (1982) Int. J. Cancer 29: 269- 75) described hybridoma technique can be produced.
- an immortalized cell line (typically a myeloma) is fused with lymphocytes (typically splenocytes or lymph node cells or peripheral blood lymphocytes) of a mammal immunized with the oligomer or derivative thereof of the invention, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma which a monoclonal antibody having specificity for oligomer according to the invention or for a derivative thereof produced.
- lymphocytes typically splenocytes or lymph node cells or peripheral blood lymphocytes
- the immortalized cell line eg, a myeloma cell line
- murine hybridomas can be established by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the invention to an immortalized mouse cell line.
- Preferred immortalized cell lines are mouse myeloma cell lines which are sensitive to hypoxanthine, aminopterin and thymidine-containing culture medium (HAT medium).
- HAT medium thymidine-containing culture medium
- One of many myeloma cell lines can be used as standard by fusion, eg the P3-NS1 / 1-Ag4-1, P3-x63-Ag8.653 or Sp2 / O-Ag14 myeloma line. These myeloma cell lines are available from the American Type Culture Collection (ATCC), Rockville, MD.
- ATCC American Type Culture Collection
- HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol (PEG).
- Monoclonal antibody-producing hybridoma cells specifically recognizing oligomer or derivative thereof of the present invention are identified by screening the hybridoma culture supernatants for such antibodies, eg, by using a standard ELISA assay to select those antibodies, the oligomer of the invention or a derivative thereof can specifically bind.
- mice can be used for in vivo immunization.
- a host expressing an endogenous version of the antigen of interest itself may be used.
- a host deficient for an endogenous version of the antigen of interest may be used. It has been shown, for example, that mice made deficient for a particular endogenous protein (ie, knockout mice) via homologous recombination on the corresponding endogenous gene produce a humoral response to the protein with which they were immunized, and thus to produce high affinity monoclonal antibodies Antibodies against the protein can be used (see, eg, Roes, J. et al., (1995) J. Immunol., Methods 183: 231-237; Lunn, MP et al. (2000) J. Neurochem. 75: 404-412). ,
- non-human mammals are useful as hosts for antibody production. These include mice, rats, chickens, camelids, rabbits and goats (and knockout versions thereof), although mice are preferred for hybridoma production.
- non-human host animal expressing a human antibody repertoire.
- Such non-human animals include transgenic animals (e.g., mice) carrying human immunoglobulin transgenes (chimeric hu-PBMC-SCID mice) and human / mouse irradiation chimeras, described in more detail below.
- the animal immunized with an oligomer or derivative thereof of the invention is a non-human mammal, preferably a mouse, that is transgenic by human immunoglobulin genes such that the non-human mammal makes human antigens following an antigenic stimulus.
- human immunoglobulin genes such that the non-human mammal makes human antigens following an antigenic stimulus.
- heavy and light chain human immunoglobulin immunoglobulin transgenes are introduced into such animals with the human germline configuration Animals have been altered so that their endogenous loci for heavy and light chain are inactive. Stimulating such animals with antigen (eg, with a human antigen) produces antibodies derived from the human immunoglobulin sequences (ie, human antibodies). From the lymphocytes of such animals, human monoclonal antibodies can be made by standard hybridoma technology.
- transgenic mice with human immunoglobulins and their use in the production of human antibodies, see, for example, U.S. Patent Nos. 5,939,598, WO 96/33735, WO 96/34096, WO 98/24893 and WO 99/53049 (Abgenix Inc.), and U.S. Patent No. 5,545,806, No. 5,569,825, No. 5,625, 126, No. 5,633, 425, No. 5,661,016, No. 5,625,816.
- the animal immunized with the oligomer or derivative thereof of the invention may be a severe combined immunodeficiency (SCID) mouse reconstituted with human peripheral blood mononuclear cells or lymphoid cells or progenitors thereof.
- SCID severe combined immunodeficiency
- Such mice termed chimeric hu-PBMC-SCID mice, have been shown to produce human immunoglobulin responses to an antigenic stimulus.
- chimeric hu-PBMC-SCID mice have been shown to produce human immunoglobulin responses to an antigenic stimulus.
- leaders K.A. he al. (1992) Immunology 76: 229-234; Bombil, F. et al. (1996) Immunobiol. 195: 360-375; Murphy, W.J. he al. (1996) Semin. Immunol. 8: 233-241; Herz, U. et al. (1997) Int. Arch. Allergy Immunol. 113: 150-152; Albert, S.E. he al.
- the animal which is immunized with oligomer according to the invention or a derivative thereof is a mouse which is lethal Irradiated with bone marrow cells from mice with severe combined immunodeficiency (SCID) and then transplanted with functional human lymphocytes.
- SCID severe combined immunodeficiency
- This type of chimera called the Trimera system, is used to make human monoclonal antibodies by immunizing the mice with the antigen of interest and then producing monoclonal antibodies using standard hybridoma technology.
- these mice and their use for the generation of antibodies see, for example, Eren, R. et al. (1998) Immunology 93: 154-161; Reisner, Y and Dagan, S. (1998) Trends Biotechnol. 16: 242-246; llan, E. he al. (1999) Hepatology 29: 553-562; and Bocher, WO et al. (1999) Immunology 96: 634-641.
- antibodies according to the invention can be identified and isolated by screening recombinant combinatorial immunoglobulin libraries with an oligomer or derivative thereof according to the invention, thus members of the immunoglobulin library specific to the oligomer or derivative thereof, to isolate.
- Kits for generating and screening display banks are commercially available (e.g., the Recombinant Phage Antibody System from Pharmacia, Catalog No. 27-9400-01; and the SurfZAP® Phage Display Kit from Stratagene, catalog # 240612).
- the display bank is an scFv bank or a fab bank. The phage display technique for screening recombinant antibody libraries has been well described.
- WO 92/09690 (specifically describes phage expression techniques); Knappik he al. WO 97/08320 (describes the human recombinant antibody library HuCal); Salfeld he al. WO 97/29131, (describes the production of a recombinant human Antibody to a human antigen (human tumor necrosis factor alpha), as well as in vitro affinity maturation of the recombinant antibody) and Salfeld et al. US Provisional Application No. 60 / 126,603 and the patent applications based thereon (also describes the production of recombinant human antibodies to human antigen (human interleukin-12), as well as the in vitro affinity maturation of the recombinant antibody).
- recombinant antibody libraries can be expressed on the surface of yeast cells or bacterial cells. Methods for the preparation and screening of benches expressed on the surface of yeast cells are described in WO 99/36569. Methods for preparing and screening banks that are expressed on the surface of bacterial cells are described in more detail in WO 98/49286.
- the DNAs encoding the antibody light and heavy chains are isolated by standard molecular biology techniques, for example, by PCR amplification of DNA from the display package (eg, the phage) isolated during the screening of the bank.
- Nucleotide sequences of genes for light and heavy antibody chains, with which PCR primers can be prepared, are known in the art. Many such sequences are described, for example, in Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Pat. Department of Health and Human Services, NIH Publication No. 91-3242 and the database of sequences of human germ line VBASE.
- An antibody or antibody portion of the invention may be produced by recombinantly expressing the genes for immunoglobulin light and heavy chains in a host cell.
- a host cell having one or more recombinant expression vectors carrying DNA fragments encoding the antibody light and heavy immunoglobulin chains, such that the light and heavy chains are expressed in the host cell, and preferably into the medium in which the host cells are cultured; be secreted. From this medium, the antibodies can be obtained. Standardized recombinant DNA methodology is used to obtain genes for heavy and light antibody chains, to insert these genes into recombinant expression vectors, and to introduce the vectors into host cells.
- DNA fragments encoding the VH and VL segments of the antibody of interest can be further manipulated with standard recombinant DNA techniques, such as the variable region genes in full length antibody chain genes To convert genes for Fab fragments or into a scFv gene.
- a VL or VH-encoding DNA fragment is operatively linked to another another protein, e.g. linked to a constant antibody region or a flexible linker, encoding DNA fragment.
- the term "operatively linked” is intended to mean that the two DNA fragments are linked together in such a way that the amino acid sequences encoded by the two DNA fragments remain in-frame.
- the isolated DNA encoding the VH region can be converted into a full-length heavy chain gene by encoding the VH region-encoding DNA with another DNA heavy chain constant region (CH1, CH2 and CH3) operatively linked.
- CH1, CH2 and CH3 DNA heavy chain constant region
- the sequences of human heavy chain constant region genes are well known (see, eg, Kabat, EA, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91- 3242), and DNA fragments spanning these regions can be obtained by standard PCR amplification.
- the heavy chain constant region may be a constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD, with a constant region of IgG1 or IgG4 being preferred.
- the VH-encoding DNA can be operatively linked to another DNA molecule which only codes for the constant region CH1 of the heavy chain.
- the isolated DNA encoding the VL region can be converted into a full-length light chain gene (as well as a Fab-free chain gene) by mixing the VL-encoding DNA with another, the light-chain constant region CL Chain-coding DNA molecule operatively linked.
- the sequences of human light chain constant region genes are well known (see Kabat, EA, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 ), and DNA fragments spanning these regions can be obtained by standard PCR amplification.
- the constant region of the light chain may be a constant kappa or lambda region, with a constant kappa region being preferred.
- the VH and VL-encoding DNA fragments can be operatively linked to another fragment that encodes a flexible linker, eg, the amino acid sequence (Gly 4 -Ser) 3 , such that the VH and VL Sequences are expressed as a continuous single-chain protein with the VL and VH regions linked together via the flexible linker (see Bird et al (1988) Science 242: 423-426; Huston et al. (1988) Proc. Natl Acad., U.S.A. 85: 5879-5883, McCafferty et al., Nature (1990) 348: 552-554).
- a flexible linker eg, the amino acid sequence (Gly 4 -Ser) 3
- VH and VL single domains having specificity for oligomer of the invention or a derivative thereof can be isolated from single domain libraries by the methods described above.
- Two VH single domain chains (with or without CH1) or two VL chains or a pair of VH and VL chains of the desired specificity can be used to remove oligomers or derivatives thereof of the invention from the body.
- the DNAs encoding the partial and full length light and heavy chains can be inserted into expression vectors such that the genes are operably linked to transcriptional and translational control sequences.
- operably linked is intended to mean that an antibody gene is ligated in a vector such that transcriptional and translational control sequences within the vector fulfill their intended function of regulating the transcription and translation of the antibody gene.
- the expression vector and expression control sequences are chosen to be compatible with the expression host cell used.
- the gene for the The antibody light chain and antibody heavy chain gene can be inserted into separate vectors, or both genes are inserted into the same expression vector, which is the usual case.
- the antibody genes are inserted into the expression vector by standard methods (eg, ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt-ended ligation if no restriction sites are present).
- the expression vector may already carry constant antibody region sequences.
- one approach is to convert the VH and VL sequences into full-length antibody genes by inserting them into expression vectors that already encode the heavy or light chain constant regions, such that the VH segment is linked to the one or more CH segment (s) within the vector is operatively linked, and also the VL segment is operatively linked to the CL segment within the vector.
- the recombinant expression vector can encode a signal peptide which blocks the secretion of the
- the antibody chain gene can be cloned into the vector such that the signal peptide in reading frame is linked to the N-terminus of the antibody chain gene.
- the signal peptide may be an immunoglobulin signal peptide or a heterologous signal peptide (ie, a signal peptide from a non-immunoglobulin protein).
- the expression vectors of the invention may have regulatory sequences which control the expression of the genes for the antibody chain in a host cell.
- regulatory sequence is intended to include promoters, enhancers and other expression control elements (eg, polyadenylation sequences) that control the transcription or translation of the antibody chain genes
- promoters e.g., promoters, enhancers and other expression control elements
- polyadenylation sequences e.g., polyadenylation sequences
- Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press San Diego, CA (1990) It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences, may depend on factors such as the choice of host cell to be transformed, the desired expression level of the protein, etc.
- Preferred regulatory sequences for expression in mammalian host cells include viral elements that result in strong protein expression in mammalian cells, such as promoters and / or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter / enhancer), simian virus 40 (SV40 ) (like the SV40 promoter / enhancer), Aden ovirus (eg the adenovirus major late promoter (AdMLP for adenovirus major late promoter) and polyoma.
- CMV cytomegalovirus
- SV40 simian virus 40
- AdMLP adenovirus major late promoter
- the recombinant expression vectors of the invention may have additional sequences, such as sequences that regulate replication of the vector in host cells (eg, origins of replication) and selectable marker genes.
- the selectable marker genes facilitate the selection of host cells into which the vector has been introduced (see, eg, US Pat. Nos. 4,399,216, 4,634,665 and 5,179,017, all to Axel et al.).
- it is common for the selectable marker gene to render a host cell into which the vector has been used resistant to drugs such as G418, hygromycin or methotrexate.
- Preferred selectable marker genes include the gene for dihydrofolate reductase (DHFR) (for use in dhfr host cells with methotrexate selection / amplification) and the neo gene (for G418 selection).
- DHFR dihydrofolate reductase
- neo gene for G418 selection.
- the expression vector (s) encoding the heavy and light chains are transfected into a host cell using standard techniques.
- the various forms of the term "transfection" are intended to cover a variety of techniques commonly used to introduce exogenous DNA into a prokaryotic or eukaryotic host cell, eg, electroporation, calcium phosphate precipitation, DEAE-dextran transfection, and the like it is possible to express the antibodies of the invention either in prokaryotic or eukaryotic host cells, the expression of the antibodies in eukaryotic cells and especially in mammalian host cells is preferred, since the probability that a correctly folded and immunologically active antibody is assembled and secreted in such eukaryotic cells and, in particular, mammalian cells are higher than in prokaryotic cells
- the prokaryotic expression of antibody genes has been reported to be ineffective for the production of high yields of active antibody (Boss, MA and Wood, C.A. R. (1985) Immunology Today 6: 12-13
- Mammalian host cells which are preferred for the expression of recombinant antibodies of the invention include CHO cells (including dhfr " -CHO cells described in Urlaub and Chasin, (1980) Proc Natl. Acad., USA 77: 4216-4220 Biol. 159: 601-621), NS0 myeloma cells, COS cells, and SP2 cells are recombinant expression vectors which encode the antibody genes introduced into mammalian host cells, the antibodies are prepared by culturing the host cells until the antibody expresses in the host cells, or preferably Antibodies are secreted into the culture medium in which the host cells grow. The antibodies can be recovered from the culture medium using standardized methods for the purification of proteins.
- Host cells may also be used to produce portions of intact antibodies, such as Fab fragments or scFv molecules. Variations of the procedure described above are of course part of the invention. For example, it may be desirable to transfect a host cell with DNA encoding either the light chain or the heavy chain (but not both) of an antibody of the invention. If light or heavy chains are present which are not required for the binding of the antigen of interest, the DNA encoding either or both of such a light or heavy chain may be partially or completely removed by recombinant DNA technology. Molecules expressed by such truncated DNA molecules also belong to the antibodies of the invention.
- bifunctional antibodies may be prepared in which one heavy and one light chain are an antibody of the invention and the other heavy and light chains have specificity for any antigen other than the antigen of interest by subjecting an antibody of the invention to a second antibody by standard chemical methods cross-linked.
- an antibody of the invention or antigen binding portion thereof is a recombinant expression vector, both the antibody heavy chain and encoding the antibody light chain, mediated CaIcium phosphate by transfection into DHFR "CHO cells introduced.
- the heavy and light antibody chain genes are each operatively linked to CMV enhancer / AdMLP promoter regulatory elements to effect strong transcription of the genes .
- the recombinant expression vector also carries a DHFR gene which is linked to CHO Cells selected with the vector transfected using methotrexate selection / amplification
- the selected transformed host cells are cultured to express the heavy and light antibody chains and intact antibody is recovered from the culture medium
- Verweij discloses standardized molecular biology techniques to produce the recombinant expression vector, to transfect the host cells, to select the transformants, to cultivate the host cells, and to recover the antibody from the culture medium.
- the invention relates to a process for the synthesis of a recombinant antibody according to the invention by culturing a host cell according to the invention in a suitable culture medium until a recombinant antibody according to the invention is synthesized.
- the method may further include isolating the recombinant antibody from the culture medium.
- the recombinant antibody library is expressed in the form of RNA-protein fusions as described in WO 98/31700 by Szostak and Roberts, and in Roberts, R.W. and Szostak, J.W. (1997) Proc. Natl. Acad. Be. USA 94: 12297-12302.
- a covalent fusion is generated by in vitro translation of synthetic mRNAs carrying at their 3 'end puromycin, a peptidyl acceptor antibiotic, between an mRNA and the peptide or protein that it encodes.
- a specific mRNA from a complex mixture of mRNAs may be enriched for the oligomer of the invention or a derivative thereof based on the properties of the encoded peptide or protein (eg antibody or portion thereof) such as the binding of the antibody or portion thereof become.
- Antibodies or portions thereof encoding nucleic acid sequences derived from screening such libraries may be expressed by recombinant means in the manner described above (eg, in mammalian host cells) and further subject to further affinity maturation by either mRNA-peptide amplification in subsequent rounds. Fusions are screened by introducing mutations into the originally selected sequence (s), or by using other methods of in vitro affinity maturation of recombinant antibodies in the manner described above.
- the antibodies of the invention may also be prepared using a combination of in vivo and in vitro approaches, such as methods in which first an oligomer of the invention or a derivative thereof is allowed to act on an antibody repertoire in vivo in a host animal in order to stimulate the production of oligomer or derivative binding antibodies, and then the further antibody selection and / or antibody maturation (ie optimization) is accomplished by one or more in vitro techniques.
- such a combined method may involve first immunizing a non-human animal (eg, a mouse, rat, rabbit, chicken, camelid, goat or transgenic version thereof or a chimeric mouse) with the oligomer or derivative thereof of the invention to one To stimulate antibody response to the antigen, and then to produce and screen a phage display antibody library using immunoglobulin sequences from lymphocytes stimulated in vivo by the action of the oligomer or derivative.
- the first step of this combined approach may be performed in the manner described above in the context of the in vivo approaches, while the second step of this approach may be performed in the manner described above in connection with the in vitro approaches.
- Preferred methods for hyperimmunization of non-human animals followed by in vitro screening of phage display banks prepared from the stimulated lymphocytes include those described by BioSite Inc., see, eg, WO 98/47343, WO 91/17271, U.S. Patent No. 5,427,908 and U.S. Patent No. 5,580,717.
- a combined method involves first obtaining a non-human animal (eg, a mouse, rat, rabbit, chicken, camelid, goat, or a knockout and / or transgenic version thereof, or a chimeric mouse) with a subject of the invention
- Oligomer or derivative thereof is immunized to stimulate an antibody response against the oligomer or derivative thereof, and the lymphocytes producing the antibodies with the desired specificity are selected by screening (for example, hybridomas prepared from the immunized animals).
- the genes for the antibodies or single domain antibodies are isolated from the selected clones (by standard cloning methods, such as the reverse transcriptase polymerase chain reaction) and subjected to in vitro affinity maturation to thereby cause the
- the first step of this approach may be accomplished in the manner described above in the context of the in vivo approaches, while the second step of this approach may be accomplished in the manner described above in connection with the in vitro approaches, in particular by Methods for in vitro affinity maturation are used, such as those described in WO 97/29131 and WO 00/56772.
- the recombinant antibodies are generated from single isolated lymphocytes using a procedure known to those skilled in the art as lymphocyte antibody selection (SLAM) methods and described in US Pat. Nos. 5,627,052, WO 92/02551 and Babcock, JS he al. (1996) Proc. Natl. Acad. Be. USA 93: 7843-7848.
- SLAM lymphocyte antibody selection
- a non-human animal eg a mouse, rat, rabbit, chicken, camelid, goat, or a transgenic version thereof, or a chimeric mouse
- a non-human animal eg a mouse, rat, rabbit, chicken, camelid, goat, or a transgenic version thereof, or a chimeric mouse
- individual antibody-secreting cells are selected using an antigen-specific hemolytic plaque assay.
- the oligomer or derivative thereof, or structurally related molecules of interest can be coupled to sheep erythrocytes using a linker such as biotin, whereby individual cells secreting antibodies of appropriate specificity can be identified using the hemolytic plaque assay.
- variable regions are recovered from the cells by reverse transcriptase PCR, and these variable regions can then be ligated in conjunction with appropriate immunoglobulin constant regions (eg, human constant regions ) in mammalian host cells such as COS or CHO cells.
- immunoglobulin constant regions eg, human constant regions
- Immunogrobulin sequences of transfected host cells can then be subjected to further in vitro analysis and selection, for example by spreading the transfected cells to isolate cells expressing antibodies with the desired specificity.
- the amplified immunoglobulin sequences can be further manipulated in vitro.
- oligomer-specific antibodies obtainable by the above methods are as well the subject of the present invention as their use for the preparation of a medicament for the treatment of amyloid- ⁇ -associated dementia diseases or for the preparation of a composition for the diagnosis of amyloid- ⁇ -associated dementia diseases.
- the antibodies obtainable according to the invention include in particular antisera which can be obtained by the above methods.
- These can be full serums, ie blood obtained from the host after separation of the cellular and coagulable components, or fractions of this serum in which in particular the immunoglobulin fraction and preferably the oligomer-recognizing immunoglobulin fraction is enriched.
- Such fractions can be obtained by the methods described above in connection with antibody purification.
- the antisera of the invention are polyclonal, i. they contain antibodies of different specificity, usually of different classes and subclasses, normally all L-chain isotypes are represented and several protein epitopes are recognized.
- the antisera according to the invention are generally cross-reactive.
- the antibodies obtainable according to the invention also include monoclonal antibodies, in particular chimeric and humanized antibodies, and also oligomer-binding fragments thereof.
- the present invention relates to proteins and in particular antibodies which specifically bind to an oligomer or derivative thereof according to the invention, i. Antibody with specificity for an inventive oligomer or derivative thereof.
- the present invention also relates to parts of these proteins or antibodies, in particular antigen-binding parts thereof, i. Protein or antibody parts which bind an oligomer according to the invention or a derivative thereof.
- the antibody according to the invention is preferably selected such that it has a specific binding kinetics (eg high affinity, low dissociation, low off-rate, strong neutralizing activity) for the specific binding to oligomer or derivative thereof according to the invention.
- a specific binding kinetics eg high affinity, low dissociation, low off-rate, strong neutralizing activity
- Particularly preferred are high-affinity proteins and in particular
- proteins and in particular antibodies are preferred which bind the oligomer or derivative thereof with higher affinity than monomeric A ⁇ (1-42) protein and / or monomeric A ⁇ (1-40) protein.
- Affinity ratios of 10, 100 or 1000 are particularly preferred.
- Rate constants off k of 1 x 10 -2 s" is 1 or less, 1 x 10 -3 s -1 or less, 1 x 10 -5 s -1 or less, or 1 x 10 -5 s -1 or less, are increasingly preferred in the order given.
- antibodies of the invention that they have the activity, particularly the neutoxische activity, according to the invention oligomers or derivatives thereof with an IC 50 of 1 x 10 "6 M or less inhibit.
- Inhibition constants IC50 of 1 x 10" 7 M or less , 1 x 10 -8 M or less, 1 x 10 9 M or less, 1 x 10 -10 M or less, or 1 x 10 -11 M or less are increasingly preferred in the order given.
- the antibodies are preferably isolated antibodies. In another aspect, the antibodies are neutralizing antibodies.
- the antibodies of the invention include monoclonal and recombinant antibodies. According to many embodiments, the antibody may include an amino acid sequence derived entirely from a single species, such as a human antibody or a mouse antibody. According to further embodiments, the antibody may be a chimeric antibody or a CDR graft antibody or another form of humanized antibody.
- antibody is intended to refer to immunoglobulin molecules formed of 4 polypeptide chains, two heavy (H) chains, and two light (L) chains, which chains are usually linked by disulfide bonds composed of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region, the heavy chain constant region is made up of three domains CH1, CH2 and CH3 formed.
- Each light chain is composed of a light chain variable region (abbreviated herein as LCVR or VL) and a constant light chain region.
- the light chain constant region is formed from a domain CL.
- VH and VL regions can be further subdivided into hypervariable regions, referred to as Complementarity Determining Regions (CDRs), interspersed with more conserved regions called frame work regions (FRs).
- CDRs Complementarity Determining Regions
- FRs frame work regions
- Each VH and VL region is made up of three CDRs and four FRs arranged from the N-terminus to the C-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- antigen-binding portion of an antibody refers to one or more fragments of an antibody having specificity for an oligomer or derivative thereof of the invention, wherein the fragment or fragments are still capable of the oligomer or derivative specifically bind to it. It has been shown that the antigen-binding function of an antibody can be detected by fragments of a complete antibody. Examples of binding fragments within the meaning of the term “antigen-binding portion” of an antibody include (i) a Fab fragment, ie a monovalent fragment composed of the VL, VH, CL and CH1 domains, (ii) an F (ab 2 )
- Fragment ie a bivalent fragment, which contains two Fab fragments linked together in the hinge region via a disulfide bridge; (iii) an Fd fragment composed of the VH and CH1 domains; (iv) an Fv fragment composed of the FL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al., (1989) Nature 341: 544-546) consisting of a VH domain or VH, CH1, CH2, DH3, or VH, CH2, CH3; and (vi) an isolated complementarity determining region (CDR).
- CDR complementarity determining region
- the two domains of the Fv fragment, VL and VH are encoded by separate genes, they can further be linked together with a synthetic linker using recombinant techniques, whereby they can be produced as a single protein chain, wherein the VL- and VH regions assemble to form monovalent molecules (known as single-chain Fv (ScFv), see, eg, Bird et al (1988) Science 242: 423-426: and Huston et al (1988) Proc. Natl. Acad., USA 85: 5879-5883).
- Single-chain Fv Single-chain Fv
- Such single-chain antibodies are also to be encompassed by the term "antigen-binding portion" of an antibody
- Other forms of single-chain antibodies such as "diabodies” are also included.
- Diabodies are bivalent, bispecific Antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short for the two domains to co-assemble on the same chain, thereby forcing the domains with complementary domains pairing another chain and forming two antigen-binding sites (see, eg, Holliger, P., et al., (1993) Proc Natl Acad., USA 90: 6444-6448, Poljak, RJ, et al. Structure 2: 1121-1123).
- an antibody or antigen-binding portion thereof may be part of a larger immunoadhesive molecule formed by covalent or non-covalent association of the antibody or antibody portion with one or more other proteins or peptides.
- immunoadhesion molecules include the use of the streptavidin core region to produce a more tetrameric scFv molecule (Kipriyanov, SM, et al., (1995) Human Antibodies and Hybridomas 6: 93-101) and the use of a cysteine residue, a marker peptide and a C - terminal polyhistidine tags to make bivalent and biotinylated scFv molecules (Kipriyanov, SM, et al., (1994) Mol.
- Antibody parts such as Fab and F (ab ') 2 fragments, can be made from whole antibodies using conventional techniques, such as digestion with papain or pepsin.
- antibodies, antibody parts and immunoadhesion molecules can be obtained using standard recombinant DNA techniques.
- An "isolated antibody having specificity for an oligomer or derivative thereof" according to the invention means an antibody having specificity for an oligomer or derivative thereof according to the invention which is substantially free of other antibodies with different antigen specificities, ie in particular an antibody which is free of antibodies, which specifically bind to other forms of the A ⁇ (1-42) protein as described above.
- neutralizing antibody an antibody whose binding to a particular antigen results in the inhibition of the biological activity of the antigen. This inhibition of the biological activity of the antigen can be assessed by measuring one or more indicators of the biological activity of the antigen, using a suitable in vitro or in vivo assay.
- the term "monoclonal antibody” means an antibody derived from a hybridoma (e.g., an antibody derived from a hybridoma) Hybridoma technology, as the standard Hybridommethodik after Kohler and Milstein, produced hybridoma is secreted).
- a hybridoma-derived antibody having specificity for an oligomer or derivative thereof according to the present invention is therefore referred to as a monoclonal antibody.
- recombinant antibody refers to antibodies produced, expressed, generated or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell; antibodies that are isolated from a recombinant combinatorial antibody library Antibodies isolated from an animal (e.g., a mouse) transgenic by human immunoglobulin genes (see, e.g., Taylor, LD, et al., (1992) Nucl. Acids Res. 20: 6287 Or antibodies generated, expressed, produced or isolated by any other means whereby certain immunoglobulin gene sequences (such as human immunoglobulin gene sequences) are assembled with other DNA sequences. "" Recombinant antibodies include, for example, chimeric , CDR graft and humanized antibodies.
- human antibody refers to antibodies whose variable and constant regions are human germline immunoglobulin sequences as described, for example, by Kabat et al., (See Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242), but the human antibodies of the invention may include amino acid residues other than human germline.
- Immunoglobulin sequences e.g., mutations introduced by in vivo or by somatic mutation in vivo by random or site-directed mutagenesis
- CDRs CDR3
- Recombinant human antibodies of the present invention have variable regions and may also include constant regions derived from human germline immunoglobulin sequences (see Kabat, EA, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242).
- such recombinant human antibodies are subjected to in vitro mutagenesis (or if an animal is transgenic through human Ig sequences, in vivo somatic mutagenesis) such that the amino acid sequences of the VH and VL regions are recombinant antibody Sequences, although related to or derived from human germ line VH and VL sequences, do not naturally exist within the human antibody germ line repertoire in vivo.
- such recombinant antibodies are the result of selective mutagenesis or reverse mutation, or both.
- reverse mutation refers to a method in which some or all of the somatic mutant amino acids of a human antibody are replaced with the corresponding germline residues of a homologous germline antibody sequence.
- the heavy and light chain sequences of a human antibody of the invention are separately compared to the germline sequences in the VBASE database to identify the most homologous sequences. Signs in the human antibody of the invention are attributed to the germline sequence by mutating at defined nucleotide positions encoding such aberrant amino acids.
- the direct or indirect significance of each amino acid for antigen binding thus identified as a candidate for reverse mutation should be examined, and an amino acid which, upon mutation, interferes with a desirable property of the human antibody should not be included in the final human antibody.
- those amino acid positions which differ from the closest germline sequence but are identical to the corresponding amino acid sequence of a second germline sequence can be kept unchanged, provided that the second germline sequence has the sequence of the human antibody according to the invention is identical and co-linear at least in 10 and preferably in 12 amino acids on both sides of the amino acid in question.
- Reverse mutations can be made at any stage of antibody optimization.
- chimeric antibody refers to antibodies that include heavy and light chain variable region sequences from a species, but in which the sequences of one or more of the CDR regions of VH and / or VL with CDR sequences of a are replaced by other species, such as antibodies, which have murine heavy and light chain variable regions in which one or more of the mouse CDRs (e.g., CDR3) are replaced with human CDR sequences.
- humanized antibody refers to antibodies that contain sequences of the heavy and light chain variable region from a non-human species (e.g., mouse, rat, rabbit, chicken, camelid, goat), but in which at least a portion of the art VH and / or VL sequence has been altered to be more "human-like", ie more similar to human germ line variable sequences.
- a non-human species e.g., mouse, rat, rabbit, chicken, camelid, goat
- One type of humanized antibody is a CDR graft antibody in which human CDR sequences are inserted into non-human VH and VL sequences to replace the corresponding non-human CDR sequences.
- surface plasmonresonance refers to an optical phenomenon that can be used to analyze biospecific interactions by detecting changes in protein concentrations with a biosensor matrix using, for example, the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ
- BIAcore Pharmaacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ
- Jönsson, U., et al. (1993) Ann. Biol. Clin. 5: 19-26
- K off refers to the off-rate constant for the dissociation of an antibody from the antibody / antigen complex.
- K d refers to the dissociation constant of a particular antibody-antigen interaction.
- the binding affinity of the antibodies of the invention can be assessed using standardized in vitro immunoassays such as ELISA or BIAcore analyzes.
- the protein may be a T-cell receptor-derived molecule or a T-cell receptor-derived receptor domain, or a fusion protein of the receptor domain with a Fc portion of an immunoglobulin.
- compositions comprising a protein according to the invention and in particular a Antibodies according to the invention and optionally a pharmaceutically acceptable carrier.
- Pharmaceutical compositions according to the invention may further comprise at least one additional therapeutic agent, e.g. B. one or more additional therapeutic agents for the treatment of a disease, the alleviation of the antibodies of the invention are useful include.
- the pharmaceutical composition may further include one or more additional therapeutic agents useful for the treatment of diseases in which the activity of the oligomer is important.
- Pharmaceutically acceptable carriers include all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, as long as they are physiologically compatible.
- Pharmaceutically acceptable carriers include, for example, water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols, such as mannitol or sorbitol, or sodium chloride.
- Pharmaceutically acceptable carriers may further include minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers which increase the shelf life or efficacy of the antibodies.
- the pharmaceutical compositions may be suitable for parenteral administration, for example.
- the antibodies are preferably prepared as injectable solutions with an antibody content of 0.1-250 mg / ml.
- the injectable solutions may be formulated in liquid or lyophilized form in a flint glass or vial, ampoule or filled syringe as a dosage form.
- the buffer may contain L-histidine (1-50 mM, preferably 5-10 mM) and have a pH of 5.0-7.0, preferably 6.0.
- Other suitable buffers include, but are not limited to, sodium succinate, sodium citrate, sodium phosphate or potassium phosphate buffer.
- Sodium chloride may be used to adjust the tonicity of the solution to a concentration of 0-300 mM (preferably 150 mM for a liquid dosage form).
- Cryoprotectants may be included for a lyophilized dosage form, eg sucrose (eg 0-10%, preferably 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose.
- Fillers can be used for a lyophilized dosage form, for example mannitol (eg 1 - 10%, preferably 2 - 4%).
- Stabilizers can be used in both liquid and lyophilized dosage forms, eg L-methionine (eg 51-50 mM, preferably 5-10 mM).
- Suitable bulking agents include glycine and arginine.
- surfactants may be used, for example polysorbate 80 (eg 0-0.05%, preferably 0.005-0.01%).
- surfactants include polysorbate-20 and BRIJ surfactants.
- compositions of the invention can take a variety of forms. These include liquid, semi-solid and solid dosage forms such as liquid solutions (eg injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
- liquid solutions eg injectable and infusible solutions
- dispersions or suspensions tablets, pills, powders, liposomes and suppositories.
- the preferred form depends on the intended mode of administration and therapeutic application.
- compositions in the form of injectable or infusible solutions are preferred, for example
- compositions that are similar to the passive immunization of humans with other antibodies.
- the preferred route of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular).
- the antibody is administered by intravenous infusion or injection.
- the antibody is administered by intramuscular or subcutaneous injection.
- compositions typically must be sterile and stable under the conditions of manufacture and storage.
- the compositions may be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable for high drug concentrations.
- Sterile injectable solutions can be prepared by incorporating the active compound (ie antibody) in the required amount into a suitable solvent, optionally with one or a combination of the above ingredients as needed, and then sterile-filtering.
- Dispersions are typically prepared by incorporating the active compound in a sterile vehicle containing a base dispersion medium and optionally other ingredients needed.
- a sterile lyophilized powder for the preparation of sterile injectable solutions vacuum drying and spray drying are preferred methods of preparation by which a powder of the active ingredient and optionally other desirable ingredients are obtained from a previously sterile-filtered solution.
- the right Flowability of a solution can be maintained by, for example, using a coating such as lecithin, maintaining the required particle size in the case of dispersions, or using surfactants.
- Prolonged absorption of injectable compositions can be achieved by incorporating an agent which retards absorption, e.g., monostearate salts and gelatin, into the composition.
- the antibodies of the invention may be administered by a variety of methods known to those skilled in the art, although for many therapeutic applications, subcutaneous injection, intravenous injection or infusion is the preferred mode of administration.
- the person skilled in the art knows that the route and / or mode of administration depends on the desired result.
- the active compound may be formulated with a carrier that protects the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- a controlled release formulation including implants, transdermal patches, and microencapsulated delivery systems.
- Biodegradable biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
- the methods for preparing such formulations are well known to those skilled in the art, see, for example, Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
- an antibody of the invention can be administered orally, for example in an inert diluent or an assimilable edible carrier.
- the antibody (and other ingredients if desired) may also be enclosed in a hard or soft gelatin capsule, compressed into tablets or added directly to the diet.
- the antibodies may be mixed with excipients and used in the form of swallowable tablets, buccal tablets, capsules, elixirs, suspensions, syrups and the like. If an antibody according to the invention is to be administered by a route other than the parenteral route, it may be necessary to choose a coating of a material which prevents its inactivation.
- the antibodies of the invention are preferably capable of neutralizing, both in vitro and in vivo, the activity of oligomers of the invention or derivatives thereof to which they bind.
- the antibodies can therefore inhibit activity Oligomers according to the invention or derivatives thereof are used, for.
- the subject matter of the invention is a method for inhibiting the activity of oligomers or derivatives thereof according to the invention, wherein an antibody according to the invention is allowed to act on an oligomer or derivative thereof in such a way that the activity of the oligomer or derivative thereof is inhibited.
- the activity can be inhibited, for example, in vitro.
- the antibody of the present invention may be added to a cell culture containing or suspected of containing the oligomer or derivative thereof of the present invention to inhibit the activity of the oligomer or the derivative thereof in the culture.
- the activity of the oligomer or derivative thereof in a subject can be inhibited in vivo.
- another aspect of the present invention relates to a method of inhibiting the activity of oligomers or derivatives thereof of the invention in a subject afflicted with a disease involving amyloid ⁇ -protein and, in particular, the activity of the oligomer or derivative thereof of the invention is.
- This method involves the administration of at least one antibody of the invention to the subject for the purpose of inhibiting the activity of the oligomer or derivative thereof to which or which the antibody binds.
- the individual is preferably a human.
- An antibody of the invention may be administered to a human subject for therapeutic purposes.
- an antibody of the invention may be administered to a non-human mammal for veterinary purposes or as part of an animal model for a particular disease. Such animal models may be useful to assess the therapeutic efficacy of antibodies of the invention (e.g., to test dosages and timing of administration).
- oligomers or derivatives thereof according to the invention play a role include, in particular, diseases in whose formation and / or course an oligomer or derivative thereof according to the invention is involved. This means in particular those diseases in which oligomers or derivatives thereof according to the invention demonstrably or presumably for the
- Pathophysiology of the disease or represent a factor that contributes to the development and / or course of the disease. Accordingly these include those diseases in which the inhibition of the activity of oligomers or derivatives thereof according to the invention is able to alleviate symptoms and / or progression of the disease. Such diseases can be demonstrated, for example, by the fact that an increased concentration of oligomers according to the invention or derivatives thereof in a biological fluid of an individual suffering from a particular disease (eg an increased concentration in serum, plasma, CSF, urine, etc.). ). This can be detected, for example, by using an antibody according to the invention.
- the oligomers and derivatives thereof of the invention play a crucial role in pathology associated with a variety of diseases involving neurodegenerative elements, cognitive deficits, neurotoxic elements and inflammatory elements.
- the antibodies of the invention may be administered together with one or more additional therapeutic agents useful in the treatment of the diseases described above.
- compositions of the present invention will generally contain a therapeutically effective amount or a prophylactically effective amount of at least one antibody of the invention.
- dosage plans can be selected and adjusted. For example, one can administer a single dose, several separate doses over time or administer an increasing or decreasing dosage depending on the requirements of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in unit dosage form to facilitate administration and to ensure uniformity of dosage.
- a therapeutically or prophylactically effective amount of an antibody according to the invention may for example be in the range of 0.1-20 mg / kg and preferably 1-10 mg / kg, without being limited thereto. Of course, these amounts may vary depending on the nature and severity of the condition to be alleviated.
- the qualitative or quantitative specific oligomer determination serves, in particular, for the diagnosis of disease-relevant amyloid ⁇ (1-42) forms.
- Specificity means in this The possibility to detect a specific oligomer or oligomer mixture with sufficient sensitivity.
- the antibodies according to the invention advantageously have sensitivities of less than 10 ng / ml of sample, preferably less than 1 ng / ml of sample, and more preferably less than 100 pg / ml of sample. By this is meant that at least the respectively indicated concentration of oligomer per ml of sample can be detected with the antibodies according to the invention, advantageously also lower concentrations.
- the determination is made immunologically. In principle, this can be done with any analytical or diagnostic test method in which antibodies are used. These include agglutination and precipitation techniques, immunoassays, immunohistochemical methods, and immunoblot techniques, e.g. Western blotting or dot blotting. Also in vivo methods include, for example, imaging methods.
- immunoassays Both competitive immunoassays, i. Antigen and labeled antigen (tracer) compete for antibody binding, as well as sandwich immunoassays, i. the binding of specific antibodies to the antigen is detected with a second, mostly labeled antibody.
- sandwich immunoassays i. the binding of specific antibodies to the antigen is detected with a second, mostly labeled antibody.
- assays can be both homogeneous, i. without a solid and liquid phase separation, as well as being heterogeneous, i. bound labels are separated from unbound ones, for example via solid phase bound antibodies.
- the different heterogeneous and homogeneous immunoassay formats can be assigned to specific classes depending on the labeling and measuring method, for example RIAs (radioimmunoassays), ELISA (enzyme linked immunosorbent assay), FIA (fluorescence immunoassay), LIA (luminescence immunoassay), TRFIA (temporal resolved FIA), IMAC (immune activation), EMIT (enzyme multiplied immune test), TIA (turbidimetric immunoassay), l-PCR (immuno-PCR).
- RIAs radioimmunoassays
- ELISA enzyme linked immunosorbent assay
- FIA fluorescence immunoassay
- LIA luminescence immunoassay
- TRFIA temporary resolved FIA
- IMAC immunoassay
- EMIT enzyme multiplied immune test
- TIA turbidimetric immunoassay
- l-PCR immuno-PCR
- oligomer determination For the oligomer determination according to the invention, competitive immunoassays are preferred. Labeled oligomer (tracer) competes with the sample oligomer to be quantified for binding to the antibody used. From the amount of displaced tracer can be determined using a standard curve, the amount of antigen, that is, the amount of oligomer in the sample.
- enzymes have proven to be advantageous.
- systems based on peroxidases especially horseradish peroxidase, may be alkaline Phosphatase and the ß-D-galactosidase can be used.
- specific substrates are available whose implementation can be followed, for example, photometrically.
- Suitable substrate systems are based on p-nitrophenyl phosphate (p-NPP), 5-bromo-4-chloro-3-indolyl phosphate / nitroblue tetrazolium (BCIP / NPT), fast red / naphthol AS-TS phosphate for alkaline phosphatase; 2,2-Azino-bis- (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), o-phenylenediamine (OPT), 3,3 ', 5,5'-tetramethylbenzidine (TMB), o-dianisidine, 5-aminosalicylic acid , 3-dimethylaminobenzoic acid (DMAB) and 3-methyl-2-benzothiazoline hydrazone (MBTH) for peroxidases; o-Nitrophenyl- ⁇ -D-galactoside (o-NPG), p-nitrophenyl- ⁇ -D-galactoside and 4-methylumbelliphenyl- ⁇
- Tracers used are labeled oligomers. In this sense, to determine a particular oligomer to mark the oligomer to be determined and use as a tracer.
- the coupling of labels to oligomers for the preparation of tracers can be done in a conventional manner.
- the above statements on the derivatization of oligomers according to the invention are referred to by analogy.
- a number of labels suitably modified for conjugation to proteins are available, for example, biotin, avidin, extravidin or streptavidin-conjugated enzymes, maleimide-activated enzymes, and the like.
- These labels can be reacted directly with the oligomer or, if necessary, with appropriately derivatized oligomer to form a tracer.
- a streptavidin-peroxidase conjugate this will first require biotinylation of the oligomer.
- the skilled person suitable methods are known.
- the antigen-antibody complex can be bound to the carrier for the purpose of separation, for example via an anti-idiotypic antibody coupled to the carrier, eg an antibody directed against rabbit IgG.
- Carriers in particular microtiter plates coated with appropriate antibodies, are known and in some cases commercially available.
- Another object of the present invention are immunoassay sets with at least one antibody and other components described above. This is a compilation, usually as a packaging unit, of means for carrying out an oligomer determination according to the invention. For ease of use, these agents are preferably provided ready for use substantially.
- An advantageous arrangement offers the immunoassay in kit form.
- a kit usually includes several containers for separate arrangement of components. All components may be used in ready-to-use dilution, as a dilution concentrate or as a dry substance or lyophilizate for dissolving or
- any or all of the components may be frozen or stored at ambient temperature until use.
- Sera are preferably flash-frozen, for example at -20 ° C, so that in these cases an immunoassay prior to use is preferably to be maintained at freezing temperatures.
- immunoassay Other components attached to the immunoassay are based on the type of immunoassay. As a rule, standard protein, optionally required tracer and control serum are added together with the antiserum. Further, microtiter plates, preferably coated with antibody, may be added to buffers, for example for testing, washing or reaction of the substrate, and the enzyme substrate itself.
- substances which inhibit the aggregation of the oligomers according to the invention or accelerate their disaggregation are also of interest.
- Such substances are in particular possible therapeutics for the treatment of the above amyloid- ⁇ -associated diseases, such. B. Alzheimer's disease.
- the present invention therefore also provides a process for the characterization of a substance or a mixture of substances, wherein i) the substance or the substance mixture is provided in a suitable manner; ii) the substance or the substance mixture is allowed to act on at least one oligomer according to the invention, a derivative thereof or a composition; and iii) determines whether the substance or certain portions of the substance mixture bind to the oligomer, derivative thereof or at least one oligomer or derivative thereof contained in the composition.
- This method can also be applied to mixtures of biological origin, e.g. Cell preparation and extracts to produce natural binding partners having affinity for the oligomers of the invention, e.g. Cell surface antigens, especially receptors, and soluble ligands, such as certain proteins and mediators to identify.
- biological origin e.g. Cell preparation and extracts
- natural binding partners having affinity for the oligomers of the invention, e.g. Cell surface antigens, especially receptors, and soluble ligands, such as certain proteins and mediators to identify.
- the present invention also relates to screening methods, ie both primary and secondary screening methods, in which preferably at least one of the methods described below is used. If several methods are used, this can be done with a time delay or simultaneously on one and the same sample or on different samples of a substance to be investigated.
- Kits and components for carrying out this assay may be obtained commercially, for example from Amersham Pharmacia Biotech.
- solubilized or membrane-bound receptors are immobilized on scintillant-containing small fluoromicrospheres. If, for example, a radioligand binds to the immobilized receptors, the scintillation substance is excited to emit light, since the spatial proximity between scintillant and radioligand is given.
- FlashPlateR FlashPlateR technology
- Kits and components for carrying out this assay may be obtained commercially, for example from NENR Life Science Products. This principle is also based on microtiter plates (96 or 384) coated with scintillant substance.
- the substances or parts of mixtures of substances identifiable by this method as a ligand binding to the oligomer, derivative thereof or at least one oligomer or derivative thereof containing a corresponding composition thereof are as well the subject of the present invention as their use for the manufacture of a medicament for the treatment of amyloid- ⁇ - Associated, especially dementia diseases or for the preparation of a composition for the diagnosis of amyloid- ⁇ -associated, in particular dementielle diseases.
- Figure 1 is an SDS-PAGE of an A ⁇ (1 -42) oligomer A preparation (Lane A);
- Figure 2 is an SDS-PAGE of an A ⁇ (1 -42) oligomer A preparation (Lane A);
- FIG. 1 is an SDS-PAGE of a biotin A ⁇ (1-42) oligomer B preparation
- Figure 4 is an SDS-PAGE of a fluorescein A ⁇ (1-42) oligomer B preparation (lane A); of standard proteins (molecular
- Figure 5 shows a gel permeation chromatography of A ⁇ (1-42) lyophilizate containing solution compared to A ⁇ (1-42) oligomers B containing preparation
- Figure 6 is a NATIVE-PAGE of an A ⁇ (1-42) oligomer B preparation
- FIG. 7 shows the binding of (A) monomeric A ⁇ (1-42) protein and (B) the A ⁇ (1-)
- Figure 9 is an SDS-PAGE of an A ⁇ (1-42) preparation bound with trypsin (lane 2).
- Chymotrypsin (lane 3), thermolysin (lane 4), elastase (lane 5), papain (lane 6), or untreated (lane 7); as well as from
- FIG. 10 shows dot blots for the reactivity of 100 pmol (line A); 10 pmol (line B);
- Example 15a (column 3); glutaraldehyde cross-linked A ⁇ (1-42) -
- Oligomer B preparation from example 14a (column 4); according to M.P.
- Antibody 6E10 b) the polyclonal antiserum (d1) from Example 25d; c) the polyclonal antiserum (d) from Example 25c; d) the polyclonal antiserum (a1) from Example 25a; and e) the polyclonal antiserum (a2) of Example 25a;
- Figure 11 is an SDS-PAGE of an A ⁇ (20-42) oligomer B preparation
- Example 15a (lane B); A ⁇ (12-42) oligomer B preparation from Example 15b (Lane C), A ⁇ (1-42) oligomer B preparation Example 6b (lane A); as well as standard proteins (molecular marker proteins, lane D);
- Figure 12 is a gel permeation chromatography of the A ⁇ (1-42) oligomers B-
- Example 6b Preparation of Example 6b compared to A ⁇ (1-42) oligomer B-CL preparation of Example 14a.
- Figure 13 is a schematic representation of the monomeric A ⁇ (1-42) protein
- FIG. 14 shows the excitatory postsynaptic potential (fEPSP) versus time under the influence of A ⁇ (1-42) oligomers B on hippocampus sections;
- FIG. 15 shows an immunofluorescence image which shows the binding of A ⁇ (1-42) -
- Oligomer B to hippocampal rat neurons (a) compared to nonspecifically bound fluorescence (b).
- concentrations of oligomers of the invention are expressed in terms of mole of A ⁇ (1-42) monomeric polypeptide.
- ⁇ -amyloid (1-42) protein corresponds to the term amyloid ⁇ (1-42) protein.
- proteins (polypeptides) used are of human origin.
- ⁇ -amyloid (1-42) protein (abbreviated to A ⁇ (1-42); peptide-synthetic material, lyophilizate, Bachern, Germany) are dissolved in 800 ⁇ l of 1, 1.1, 3,3,3- Hexafluoro-2-propanol dissolved and incubated for 30 min at 37 ° C in an Eppendorf tube. It is then evaporated to dryness in a vacuum concentrator (Speed Vac). The residue is taken up with 88 ⁇ l of DMSO to give a 5 mM A ⁇ (1-42) stock suspension. This can be stored at -20 ° C.
- rat ⁇ -amyloid (1-42) protein (abbreviated to rat A ⁇ (1-42); peptide-synthetic material, lyophilizate, Fa. Bachern, Germany) are dissolved in 800 ⁇ l of 1,1,1,3,3 , 3- Hexafluoro-2-propanol dissolved and incubated for 30 min at 37 ° C in an Eppendorf tube. It is then evaporated to dryness in a vacuum concentrator (Speed Vac). The residue is taken up with 88 ⁇ l of DMSO to give a 5 mM rat A ⁇ (1-42) stock suspension. This can be stored at -20 ° C.
- Example 1a 60 ⁇ l of the stock solution from Example 1a are admixed with 690 ⁇ l of PBS buffer (20 mM sodium phosphate, 140 mM NaCl, pH 7.4) and adjusted to a content of 0.2% with 75 ⁇ l of 2% sodium dodecyl sulfate (SDS) solution. SDS set. It is then incubated for 5 hours at 37 ° C and centrifuged for 10 min at 10,000 g. This A ⁇ (1-42) oligomer A preparation (about 400 ⁇ M A ⁇ (1-42)) can be stored at -20 ° C.
- PBS buffer 20 mM sodium phosphate, 140 mM NaCl, pH 7.4
- SDS sodium dodecyl sulfate
- rat A ⁇ (1-42) oligomer A preparation (about 400 ⁇ M rat A ⁇ (1-42)) can be stored at -20 ° C.
- Use of oleic acid 60 .mu.l of the stock solution from Example 1a are mixed with 690 ul PBS buffer (20 mM sodium phosphate, 140 mM NaCl, pH 7.4) and adjusted to a content of 0.5% oleic acid with 75 ul of 5% oleic acid solution. It is then incubated for 5 hours at 37 ° C and centrifuged for 10 min at 10,000 g.
- This A ⁇ (1 -42) oligomer A preparation (about 400 ⁇ M A ⁇ (1-42)) can be stored at -20 ° C.
- Example 1a 60 ⁇ l of the stock solution from Example 1a are mixed with 690 ⁇ l PBS buffer (20 mM sodium phosphate, 140 mM NaCl, pH 7.4) and adjusted to a content of 0.5% lauroyl sarcosine with 75 ⁇ l 5% lauroyl sarcosine solution , It is then incubated for 5 hours at 37 ° C and centrifuged for 10 min at 10,000 g.
- This A ⁇ (1-42) oligomer A preparation (about 400 ⁇ M A ⁇ (1-42)) can be stored at -20 ° C.
- ⁇ -amyloid (1-42) protein (abbreviated to A ⁇ (1-42); peptide-synthetic material, lyophilizate, from Bachern, Germany) are taken up in 220 ⁇ l of 10 mM aqueous HCl solution and incubated for 10 minutes at room temperature incubated. Insoluble constituents are centrifuged off at 10,000 g, 5 min. The supernatant (1 mM A ⁇ (1-42)) contains the A ⁇ (1-42) protein and is processed as follows:
- hA ⁇ (1-42) oligomer A preparation (100 ⁇ M) can be stored at -20 ° C.
- Rat A ⁇ -amyloid (1-42) protein (abbreviated to Rat A ⁇ (1-42); peptide-synthetic material, lyophilizate, Fa. Bachern, Germany) are taken up in 220 ⁇ l of 10 mM aqueous HCl solution and 10 ⁇ l min incubated at room temperature. Insoluble constituents are centrifuged off at 10,000 g, 5 min. The supernatant (1 mM Rat A ⁇ (1-42)) contains the rat amyloid ⁇ (1-42) protein and is processed as follows:
- ⁇ -amyloid (1-42) protein (abbreviated to A ⁇ (1-42); peptide-synthetic material, lyophilizate, Bachem, Germany) are dissolved in 44 ⁇ l of 1% SDS / H 2 O (5 mM A ⁇ (1-42)). 5 ⁇ l of the solution are mixed with 40 ⁇ l PBS and 5 ⁇ l 2% SDS and incubated for 16 h at 37 ° C. Insoluble constituents are centrifuged off for 5 minutes at 10,000 g. The A ⁇ (1-42) oligomer A preparation (500 ⁇ M A ⁇ (1-42)) thus obtained can be stored at -20 ° C.
- rat ⁇ -amyloid (1-42) protein (abbreviated to rat A ⁇ (1-42); peptide-synthetic material, lyophilizate, Bachem, Germany) are dissolved in 44 ⁇ l of 1% SDS / H 2 O ( 5 mM rat A ⁇ (1-42)). 5 ⁇ l of the solution are mixed with 40 ⁇ l PBS and 5 ⁇ l 2% SDS and incubated for 16 h at 37 ° C. Insoluble constituents are centrifuged off for 5 minutes at 10,000 g. The rat A ⁇ (1-42) oligomer A preparation (500 ⁇ M rat A ⁇ (1-42)) thus obtained can be stored at -20 ° C.
- rat A ⁇ (1-42) protein abbreviated to rat A ⁇ (1-42); peptide-synthetic material, lyophilizate, Bachem, Germany
- 5 ⁇ l of the solution are mixed with 40 ⁇ l PBS and 5 ⁇ l 2% SDS and incubated for 16 h at 37 °
- An A ⁇ (1-42) Oligomer A solution obtained according to Example 2a is diluted with 2.475 ml of water (0.05% SDS content, 0.1 mM A ⁇ (1-42)) and incubated at 37 ° C for 20 hours , Aliquots of this A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study.
- a rat A ⁇ (1-42) oligomer A solution obtained according to Example 2b is diluted with 2.475 ml of water (0.05% SDS content, 0.1 mM rat A ⁇ (1-42)) and for 20 hours Incubated at 37 ° C. Aliquots of this rat A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study.
- An A ⁇ (1-42) Oligomer A solution obtained according to Example 2c is diluted with 2.475 ml of water (0.125% lauric acid content, 0.1 mM A ⁇ (1-42)) and incubated at 37 ° C for 20 hours. Aliquots of this A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study.
- An A ⁇ (1-42) Oligomer A solution obtained according to Example 2d is diluted with 2.475 ml of water (0.125% oleic acid content, 0.1 mM A ⁇ (1-42)) and incubated at 37 ° C for 20 hours. Aliquots of this A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study.
- An A ⁇ (1-42) oligomer A solution obtained according to Example 2e is diluted with 2.475 ml of water (0.125% laurylsarcosine content, 0.1 mM A ⁇ (1-42)) and incubated at 37 ° C for 20 hours. Aliquots of this A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study.
- An A ⁇ (1-42) oligomer B preparation prepared in accordance with Example 5a is mixed with 30 ml of PBS buffer containing 0.1% Pluronic® F68 (BASF) and concentrated in Centriprep
- biotin- ⁇ -amyloid (1-42) protein short: biotin A ⁇ (1-42), peptide synthetic material, lyophilisate, AnaSpec
- biotin A ⁇ (1-42) peptide synthetic material, lyophilisate, AnaSpec
- a vacuum concentrator Speed Vac
- the residue is taken up in 20.5 ⁇ l of DMSO to give a 5 mM biotin-A ⁇ (1-42) strain suspension. This can be stored at -20 ° C.
- a biotin-A ⁇ (1-42) Oligomer A solution obtained according to Example 8 is diluted with 82 ⁇ l of water (0.05% SDS content, 0.1 mM A ⁇ ) and incubated at 37 ° C for 16 hours. Insoluble constituents are centrifuged off at 10,000 g, 5 min.
- the BiotinA ⁇ (1-42) oligomer B preparation can be frozen at -20 ° C and stored for further studies ( Figure 3).
- fluorescein- ⁇ -amyloid (1-42) protein (short: fluorescein A ⁇ (1-42), peptide synthetic material, lyophilisate, AnaSpec) are dissolved in 200 ⁇ l of 1, 1.1, 3.3.3 -
- a ⁇ (1-42) strain suspension is formed. This can be stored at -20 ° C.
- a fluorescein A ⁇ (1-42) oligomer A solution obtained according to Example 11 is diluted with 82 ⁇ l of water (0.05% SDS content, 0.1 mM A ⁇ (1-42)) and at 37 ° for 16 hours C incubated.
- the fluorescein A ⁇ (1-42) oligomer B preparation can be frozen at -80 ° C and stored for further study ( Figure 4).
- the supernatant is removed and dialyzed for 16 h at 6 ° C in dialysis tubing against 1 I 5 mM Na-phosphate, 35 mM NaCl, pH 7.4. Thereafter, the dialysate is centrifuged for 10 min at 10,000 g and the supernatant removed. The supernatant can be stored at -80 ° C for further study.
- the resulting preparation contains cross-linked A ⁇ (1-42) oligomers B and is designated A ⁇ (1-42) oligomer B-CL preparation.
- the concentrate is treated with 9 ml of buffer (50 mM MES / NaOH, 0.02% SDS, pH 7.4) and reconcentrated to 1 ml.
- the concentrate is dialyzed for 16 h at 6 ° C against 1 l buffer (5 mM Na-phosphate, 35 mM NaCl) in the dialysis tube.
- the dialysate is adjusted to an SDS content of 0.1% with a 2% SDS solution in water.
- the sample is centrifuged for 10 min at 10,000 g and the supernatant removed.
- the batch is concentrated to about 1 ml via a 15 ml 30 kDa Centriprep tube.
- the concentrate is treated with 9 ml of buffer (5 mM sodium phosphate, 35 mM sodium chloride, pH 7.4) and reconcentrated to 1 ml.
- the concentrate is dialyzed for 16 h at 6 ° C against 1 l buffer (5 mM Na-phosphate, 35 mM NaCl) in the dialysis tube.
- the dialysate is adjusted to an SDS content of 0.1% with a 1% SDS solution in water.
- the sample is centrifuged for 10 min at 10,000 g and the supernatant removed.
- GPC gel permeation chromatography
- the column is equilibrated with 5 column volumes of PBS buffer (flow 0.5 ml / min, detection UV, 214 nm) and first calibrated with calibration proteins. Subsequently, the A ⁇ (1-42) oligomer B preparation of Example 5a ( Figure 5, bottom) and A ⁇ (1-42) lyophilizate freshly weighed and dissolved in PBS for comparison, after centrifugation for 5 minutes, are insoluble Ingredients analyzed at 10,000 g ( Figure 5 above).
- the evaluation reveals that the A ⁇ (1-42) oligomer B preparation is characterized by a major peak in the molecular weight region of about 50 kDa Having protein fraction. As under denaturing conditions in SDS-PAGE, this protein fraction differs significantly from the monomeric A ⁇ (1-42) protein characterized by a major peak in the molecular weight region of about 16 kDa.
- a ⁇ (1-42) oligomer B from Example 6b is diluted to 1 mg / ml with PBS buffer and A ⁇ (1-42) oligomer B-CL from Example 14a is diluted to 1 mg / ml with PBS buffer and analyzed (Fig. 12).
- the evaluation reveals that the A ⁇ (1-42) oligomer B preparation with reduced SDS content has a protein fraction characterized by a major peak in the molecular weight region of about 100 kDa.
- the A ⁇ (1-42) oligomer B-CL preparation with reduced SDS content has a protein fraction characterized by a major peak in the molecular weight range of about 60 kDa.
- Example 5a containing oligomers B are analyzed under non-denaturing conditions in a 4-20% tris-glycine gel.
- the detergent contained in the preparations is neutralized by the nonionic detergent Triton X-100.
- 1 .mu.l 4% Triton X-100
- 10 .mu.l of the preparation from Example 5a are pipetted to 10 .mu.l of the preparation from Example 5a and incubated for 5 min at room temperature. Thereafter, 10 ⁇ l with the same volume of native sample buffer (4 ml 1M Tris, pH 6.8, 8 ml glycerol, 1 ml bromophenol blue in 50 ml H 2 O) and the electrophoresis (running buffer: 7.5 g Tris, 36 g Glycine to 2.5 IH 2 O).
- molecular weights can also be assigned to the oligomers according to the invention, in particular to oligomers B, also in native molecular weight analysis methods such as gel permeation chromatography (see Example 17) or native gel electrophoresis (see Example 18).
- Oligomers B which can be assigned SDS-PAGE molecular weights of about 38 and 48 kDa, are detected after complexing the SDS in native gel electrophoresis as a band in the molecular weight range of about 64-90 kDa based on selected standard proteins. It is not to be expected from this method that an exact molecular weight can be read, since the running behavior of the oligomers is essentially determined by their intrinsic charges in addition to the size. However, it can be concluded from the result that a defined oligomeric species is present.
- the A ⁇ (1-42) oligomers B obtained according to Example 6b are tested for stability in PBS buffer under the following conditions.
- the A ⁇ (1-42) oligomers B obtained according to Example 6b are diluted to 0.5 mg / ml with PBS buffer and incubated for 24 hours or 96 hours at room temperature or at 37 ° C. Subsequently, the band pattern was analyzed in an SDS-PAGE. The band pattern is identical in all samples.
- Example 20
- proteases trypsin, chymotrypsin, thermolysin, elastase, papain
- SDS-PAGE shows that starting from the A ⁇ (1-42) oligomer B preparation all proteases under the selected limited proteolytic conditions reduce the double band at 38/48 kDa to a kDa double band at about 32/28 kDa.
- a ⁇ (1-42) oligomers B have high plasma stability.
- the biological half-life in the plasma is therefore in the range of about 8 hours or longer.
- Oligomer A and A ⁇ (1-42) oligomer B preparations to the human neuroblastoma cell line IMR-32 is assayed by FACScan (Beckton Dickinson).
- a suspension of IMR-32 cells (1.5x10 6 cells / 0.1 ml PBS) is probed with biotin-labeled, human ⁇ -amyloid (1-42) protein (peptide synthetic material, lyophilisate, AnaSpec) and the Biotin-labeled oligomers A and B containing preparations (Example 8 or 9) for 20 minutes at 37 ° C incubated.
- the cells are washed with buffer (PBS plus 1% BSA) and incubated with Streptavidin isothiocyanate-coupled fluorescein (Sigma) for 20 minutes at room temperature. After a buffer wash, binding to the surface of IMR-32 cells was analyzed by FACScan. The broken line shows the background fluorescence in the absence of the biotin-labeled components. The addition of the individual preparations resulted in a large increase in cell-associated fluorescence and is indicated by the thick line.
- the binding of the oligomers A ( Figure 7B) and B (Figure 7C) to the cell surfaces differs significantly from the binding of the monomeric ⁇ -amyloid (1-42) protein ( Figure 7A). The data show specific binding sites for the oligomers on human cell surfaces.
- a homogenate from a control brain of an untreated rat is carried, and a calibration series of the A ⁇ (1-42) oligomer B preparation is similarly prepared in this brain homogenate. Thereafter, the homogenates are centrifuged for 1 h at 100,000 g in the ultracentrifuge and the supernatants used for the subsequent analyzes.
- rats While no A ⁇ (1-42) (0.01 nmol / g) is detectable in the brain extracts of untreated rats, rats are approximately 0.4 nmol in the 15 min after treatment by comparing the staining intensity with the corresponding concentrations of the positive control / g A ⁇ (1-42) and in the 120 min after treatment killed rats according to the same method still about 0.2 nmol / g detectable. This results in a mean biological half-life of about 105 min for the exogenously applied A ⁇ (1-42) oligomers B.
- Anti A ⁇ (1-42) reactive bands occur only in the range 38/48 kDa, which corresponds to the apparent molecular weight of the A ⁇ (1-42) oligomers B, ie the oligomeric structure remains in vivo application even after 2 hours receive. Furthermore, the same concentrations in the brains of the 15-min rats (0.4 nmol / g) and the 120-min rats (0.2 nmol / g) can be determined by comparing the staining intensities with correspondingly intensely stained bands of A ⁇ (1-42 ) - Oligomers B are estimated in the positive control as in the Dot Blot method.
- the preparation and cultivation of murine cortical neurons occurs as a mixed culture with glial cells based on the literature (Choi et al., (1987) J. Neurosci., 7, 357-368). In embryos, on 14.-15. Development Day the cortices of the meninges and deeper brain areas mechanically freed. The cells are separated by incubation in a 0.05% trypsin solution at 37 ° C for 5-7 minutes followed by repeated pipetting through a reduced-aperture Pasteur pipette.
- the toxic effect of A ⁇ (1-42) oligomers B is examined.
- the cells are incubated for 15 minutes in brain cell buffer (120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 15 mM glucose, 25 mM HEPES, pH 7.2).
- Control cells 1 are incubated at the same time with 300 ⁇ M L-glutamate in brain cell buffer.
- the stock solution of Aß oligomers is diluted with serum-free medium (Minimum Essential Medium with 0.8 mM glutamine, 20 mM glucose, 26 mM NaHCO 3 ) to various final concentrations and incubated for 24 h.
- control cells 1 treated with L-glutamate are incubated in serum-free medium in parallel.
- Another group of cells (control cells 2) is treated only with brain cell buffer and serum-free medium.
- the cell culture supernatants are removed, the remaining cells are destroyed by incubation in distilled water for 20 minutes, and the activity of the enzyme lactate dehydrogenase (LDH) in both solutions is determined enzymatically.
- LDH lactate dehydrogenase
- control cells 1 Of the Mean in the glutamate-treated cells (control cells 1) is equated with 100% neuronal death, the mean of the cells treated with neither L-glutamate nor Aß oligomers (control cells 2), with 0% neuronal death and the values of converted accordingly with Aß oligomers treated cells.
- the mean value of the neurotoxicity of all determinations at the concentrations used in each case shows a marked toxic effect of the A ⁇ (1-42) oligomers with molecular weights of 38 kDa and 48 kDa [A ⁇ (1-42) - oligomer B], cf. Fig. 8.
- the cocktails used for immunization in all cases contain adjuvant (Biogenes) with essentially the following components:
- the adjuvant is mixed with a solution of the antigen in the ratio of 2: 1 until a stable emulsion is obtained.
- the emulsion is injected and forms a depot from which the antigen is released continuously.
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (a1).
- 2 mg of A ⁇ (20-42) oligomer B preparation from Example 15a to LPH are coupled with glutaric dialdehyde under standard conditions and 2 additional rabbits are immunized according to the standard protocol with this conjugated A ⁇ (20-42) oligomer B:
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (a2).
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (b1).
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (b2).
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (d).
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (d1).
- 2 mg of A ⁇ (1-42) oligomer B preparation from Example 6b are coupled to LPH, with glutaric dialdehyde under standard conditions and 2 additional rabbits are immunized according to the standard protocol with this conjugated A ⁇ (1-42) oligomer B preparation:
- the antisera are obtained from the rabbit blood by standing at room temperature and then centrifuging at room temperature.
- the serum thus obtained is called serum (d2).
- the numbers indicate the minimum amount of antigen visible in [pmol; except for APP in each case based on monomer] (detection limit).
- mice were immunized with A ⁇ (1-42) oligomers from Example 6b and monoclonal antibodies were established in a manner known per se. Two out of ten Hybrdidoma secrete monoclonal antibodies whose binding profiles are similar to those of the antiserum (a1), especially with respect to the reactivities tested above.
- a ⁇ 1-42
- 100 ⁇ l of 2 mg / ml A ⁇ (1-42) solution in 0.1% NH 4 OH are diluted to 0.5 mg / ml with 300 ⁇ l buffer (20 mM Na phosphate, 140 mM NaCl, pH 7.4) and extracted with 0 , 1 M HCL adjusted to pH 7.4 (100 ⁇ M A ⁇ (1-42)).
- the sample is incubated for 24 h at 37 ° C and then centrifuged for 10 min at 10,000 g.
- the resulting protein residue is resuspended with 400 ⁇ l of buffer (20 mM Na phosphate, 140 mM NaCl, pH 7.4).
- the A ⁇ (1-42) fibril preparation thus obtained can be stored at -20 ° C and used for further studies.
- Figure 14 shows that the washing-in of A ⁇ (1-42) oligomers suppresses long-term potentiation in the hippocampus, especially in the "maintenance phase.” Accordingly, the A ⁇ (1-42) oligomers have B-CL an influence on the information storage of nerve cells (cellular memory).
- rat A ⁇ (1-42) oligomers B from Example 5b was examined.
- the hippocampal neurons were cultured in neurobasal medium supplemented with B27 on poly-L-lysine coated coverslips and used on day 14 of culture.
- the binding of the oligomers to the cell membrane of the neurons was carried out by adding 200 nM (total monomeric A ⁇ concentration) oligomers in fresh culture medium and incubating for 15 min. at 37 ° C After removal of the Aß-containing medium was washed twice with medium and then fixed the cells in 3.7% formaldehyde. After further washing of the cells, nonspecific binding sites were blocked with 10% normal donkey serum in PBS buffer for 90 min at room temperature.
- 6E10 from mouse was applied at a dilution of 1: 2000 for 2 h at room temperature.
- the cells were washed again and incubated with the second antibody (from donkey), which is directed against mouse and to which the fluorescent dye Cy3 is coupled, for 2 h at room temperature.
- the coverslips with the neurons were fixed on a microscope slide with mounting medium.
- the hippocampal neurons with bound A ⁇ oligomers were displayed in a fluorescence microscope.
- Control an approach was used in which the 1st antibody 6E10 was omitted. This control thus shows the nonspecific fluorescence that is not based on A ⁇ .
- the oligomers bind to the cell surface of the
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05007964A MXPA05007964A (es) | 2003-01-31 | 2004-02-02 | Oligomeros ¦-(1,42) amiloides, derivados de los mismos y anticuerpos de estos, metodos para la preparacion de los mismos y el uso de los mismos. |
JP2006501701A JP5150097B2 (ja) | 2003-01-31 | 2004-02-02 | アミロイド−β(1−42)−オリゴマー、その誘導体及びその抗体、その製法及びその使用 |
NZ541453A NZ541453A (en) | 2003-01-31 | 2004-02-02 | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof |
EP04707201.2A EP1594891B1 (de) | 2003-01-31 | 2004-02-02 | Amyloid-beta(1-42)-oligomere, derivate davon und antikörper dafür, verfahren zu deren herstellung und deren verwendung |
BR0407084-4A BRPI0407084A (pt) | 2003-01-31 | 2004-02-02 | OligÈmero de proteìna amilóide, composição, processo para preparar oligÈmeros de uma proteìna amilóide, uso de um oligÈmero, de um seu derivado ou de uma composição, processo para caracterizar uma substância ou mistura de substâncias, substância ou uma porção de uma mistura de substâncias, uso das mesmas, processo para produzir anticorpos, anticorpo, proteìna, agente farmacêutico, uso de uma proteìna, e, vacina |
CN200480008812A CN100595210C (zh) | 2003-01-31 | 2004-02-02 | 淀粉样β(1-42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途 |
US10/543,841 US7902328B2 (en) | 2003-01-31 | 2004-02-02 | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
CA2514582A CA2514582C (en) | 2003-01-31 | 2004-02-02 | Amyloid-.beta.(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof |
ES04707201.2T ES2567437T3 (es) | 2003-01-31 | 2004-02-02 | Oligómeros beta-(1,42) amiloides, derivados de los mismos y anticuerpos para estos, métodos para la preparación de los mismos y uso de los mismos |
AU2004207075A AU2004207075B2 (en) | 2003-01-31 | 2004-02-02 | Amyloid-beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
IL197312A IL197312A0 (en) | 2003-01-31 | 2009-02-26 | Amyloid-??(1-42) oligomers, derivatives thereof antibodies for the same, method for production and use thereof |
US12/559,255 US20100209346A1 (en) | 2003-01-31 | 2009-09-14 | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
IL205430A IL205430A0 (en) | 2003-01-31 | 2010-04-29 | An antibody specifically binding to an oligomer comprising an a?? fragment or an antigen - binding portion thereof and pharmaceutical composition comprising them |
AU2010257323A AU2010257323B8 (en) | 2003-01-31 | 2010-12-22 | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
IL212997A IL212997A0 (en) | 2003-01-31 | 2011-05-19 | An antibody that binds specifically to an aligomeric amyloid b (1-42) and processes for its production |
US13/195,533 US9176150B2 (en) | 2003-01-31 | 2011-08-01 | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US14/864,526 US10464976B2 (en) | 2003-01-31 | 2015-09-24 | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10303974.0 | 2003-01-31 | ||
DE10303974A DE10303974A1 (de) | 2003-01-31 | 2003-01-31 | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/543,841 A-371-Of-International US7902328B2 (en) | 2003-01-31 | 2004-02-02 | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US10/543,841 Substitution US7902328B2 (en) | 2003-01-31 | 2004-02-02 | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US12/559,255 Division US20100209346A1 (en) | 2003-01-31 | 2009-09-14 | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004067561A1 true WO2004067561A1 (de) | 2004-08-12 |
Family
ID=32667945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/000927 WO2004067561A1 (de) | 2003-01-31 | 2004-02-02 | AMYLOID-β(1-42)-OLIGOMERE, DERIVATE DAVON UND ANTIKÖRPER DAFÜR, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG |
Country Status (15)
Country | Link |
---|---|
US (4) | US7902328B2 (de) |
EP (4) | EP2336161B1 (de) |
JP (4) | JP5150097B2 (de) |
KR (3) | KR20120042959A (de) |
CN (3) | CN100595210C (de) |
AU (2) | AU2004207075B2 (de) |
BR (1) | BRPI0407084A (de) |
CA (2) | CA3000519A1 (de) |
DE (1) | DE10303974A1 (de) |
ES (1) | ES2567437T3 (de) |
IL (3) | IL197312A0 (de) |
MX (1) | MXPA05007964A (de) |
NZ (2) | NZ541453A (de) |
WO (1) | WO2004067561A1 (de) |
ZA (1) | ZA200506934B (de) |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006094724A2 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
WO2007005359A1 (en) * | 2005-06-30 | 2007-01-11 | Merck & Co., Inc. | Composition and method for producing stable amyloid beta oligomers of high molecular weight |
WO2007062852A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES |
WO2007064972A2 (en) * | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
JP2008531635A (ja) * | 2005-03-05 | 2008-08-14 | アボット ゲーエムベーハー ウント カンパニー カーゲー | スクリーニング方法、非拡散性aベータオリゴマーの精製方法、前記非拡散性aベータオリゴマーに対する選択的抗体および前記抗体の製造方法 |
WO2008104385A1 (en) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
JP2009518010A (ja) * | 2005-11-30 | 2009-05-07 | アボット・ラボラトリーズ | ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用 |
EP2097104A2 (de) * | 2006-11-30 | 2009-09-09 | Abbott Laboratories | Neue monoklonale a-beta-konformer-selektive anti-a-beta-globulomer-antikörper |
WO2010010469A2 (en) * | 2008-07-25 | 2010-01-28 | Abbott Gmbh & Co. Kg | Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US7763250B2 (en) | 2005-04-29 | 2010-07-27 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and nucleic acids encoding same |
WO2010104815A1 (en) | 2009-03-10 | 2010-09-16 | Abbott Laboratories | Antibodies binding to pivka-ii amino acids 13-27 |
US7807165B2 (en) | 2004-07-30 | 2010-10-05 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
EP2273273A1 (de) * | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer |
WO2011026017A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Laboratories | Biomarkers for prediction of major adverse cardiac events and uses thereof |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US7939075B2 (en) | 2007-01-11 | 2011-05-10 | Philipps-Universitaet Marburg | Human monoclonal anti-amyloid-beta antibodies |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012018476A1 (en) | 2010-07-26 | 2012-02-09 | Abbott Laboratories | Antibodies relating to pivka-ii and uses thereof |
WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
US8129389B2 (en) | 2005-03-24 | 2012-03-06 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing the latter and use thereof |
US8168188B1 (en) | 2004-08-11 | 2012-05-01 | Kyoto University | Antibody and utilization of the same |
EP2486928A1 (de) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
US8250823B2 (en) | 2003-08-26 | 2012-08-28 | Ejot Gmbh & Co. Kg | Dowels and methods for the assembly of insulating panels |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US8796439B2 (en) | 2006-07-14 | 2014-08-05 | Ac Immune S.A. | Nucleic acid molecules encoding a humanized antibody |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2865670A1 (de) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thioharnstoffderivative als Glutaminylcyclaseinhibitoren |
WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
US9102722B2 (en) | 2012-01-27 | 2015-08-11 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
CN105924521A (zh) * | 2005-11-30 | 2016-09-07 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
US9688734B2 (en) | 2008-04-14 | 2017-06-27 | Alzinova Ab | Stable amyloid beta monomers and oligomers |
EP3461819A1 (de) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Hemmer der glutaminylcyclase |
WO2019121263A1 (de) * | 2017-12-18 | 2019-06-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Verfahren zur auftrennung verschiedener abeta-peptide durch gelelektrophorese |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
DE10259382A1 (de) * | 2002-12-18 | 2004-07-01 | Abbott Gmbh & Co. Kg | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
AU2013200177B2 (en) * | 2005-11-30 | 2014-10-02 | Abbvie Deutschland Gmbh & Co Kg | Monoclonal antibodies against amyloid beta protein and uses thereof |
PE20100748A1 (es) * | 2005-12-12 | 2010-11-12 | Hoffmann La Roche | Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
KR101591223B1 (ko) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
ES2323725T3 (es) * | 2006-07-28 | 2009-07-23 | Vista Ventures Gmbh | Procedimiento para la deteccion de oligomeros de amiloide beta en fluidos corporales. |
WO2008070284A2 (en) | 2006-10-16 | 2008-06-12 | Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute | Amyloid beta peptides and methods of uses thereof |
US7618944B2 (en) * | 2007-03-01 | 2009-11-17 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
AU2008267038B2 (en) * | 2007-06-12 | 2014-08-07 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
CA2690434C (en) * | 2007-06-12 | 2018-05-22 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
CA2701788C (en) * | 2007-10-05 | 2017-06-13 | Genentech, Inc. | Humanized beta-amyloid antibody for treating ocular diseases |
SG178809A1 (en) * | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
SG185316A1 (en) * | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
WO2009056490A1 (en) * | 2007-10-29 | 2009-05-07 | Innogenetics Nv | NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
ES2617604T3 (es) * | 2008-02-08 | 2017-06-19 | Immunas Pharma, Inc. | Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización |
US20090239888A1 (en) * | 2008-02-12 | 2009-09-24 | Wisconsin Alumni Research Foundation | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation |
CN102203124A (zh) * | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物,其寡聚物,用于制备的方法以及包括所述类似物或寡聚物的组合物,及其用途 |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2258398A1 (de) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin/Amyloidpeptid-Konjugate und deren Verwendungen |
CN102596997B (zh) | 2009-08-06 | 2015-06-03 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
EP2462161B1 (de) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
WO2013013056A1 (en) | 2011-07-19 | 2013-01-24 | New York University | Method for treating amyloid disease |
WO2013012811A2 (en) * | 2011-07-19 | 2013-01-24 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
CA2867338A1 (en) * | 2012-03-13 | 2013-09-19 | Janssen Alzheimer Immunotherapy | Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease |
US9464118B2 (en) * | 2012-04-05 | 2016-10-11 | Forschungszentrum Juelich Gmbh | Polymers containing multivalent amyloid-beta-binding D-peptides and their use |
WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
BR112017018209A2 (pt) * | 2015-02-27 | 2018-04-17 | Board Of Regents, The University Of Texas System | produtos terapêuticos de polipeptídeo e usos dos mesmos |
RS62986B1 (sr) | 2015-06-24 | 2022-03-31 | Hoffmann La Roche | Antitela na transferinski receptor sa prilagođenim afinitetom |
US11402328B2 (en) | 2015-09-29 | 2022-08-02 | Hamamatsu Photonics K.K. | Amyloid β oligomer detection method, amyloid β oligomer detection device, and amyloid β oligomer detection program |
TWI747843B (zh) | 2015-10-02 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
AU2019339260A1 (en) | 2018-09-10 | 2021-03-25 | Lung Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
CN110412294B9 (zh) * | 2019-08-07 | 2023-05-26 | 深圳市新产业生物医学工程股份有限公司 | 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法 |
CN113308439B (zh) * | 2020-11-06 | 2023-05-05 | 华中科技大学 | 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
WO2023107830A1 (en) * | 2021-12-06 | 2023-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Amyloid oligomer compositions |
WO2023149801A1 (en) * | 2022-02-03 | 2023-08-10 | Erasmus University Medical Center Rotterdam | Method for preparing a conformation-specific antibody. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001010900A2 (en) * | 1999-08-04 | 2001-02-15 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
Family Cites Families (722)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2500076C3 (de) | 1975-01-02 | 1982-11-18 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4526039A (en) | 1983-06-23 | 1985-07-02 | The United States Of America As Represented By The Secretary Of Transportation | Removable strain gauge fixture and method for measuring accumulated strain in a material |
US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5107065A (en) | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
US5231170A (en) | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5525339A (en) | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
JPS63240797A (ja) | 1986-10-14 | 1988-10-06 | Shin Etsu Chem Co Ltd | モノクローナル抗体、その製法およびそれを含有する診断薬 |
EP0332640A1 (de) | 1986-11-17 | 1989-09-20 | California Biotechnology, Inc. | Rekombinantes alzheimer-amyloidprotein |
DE3702789A1 (de) | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
JPS63245689A (ja) | 1987-03-31 | 1988-10-12 | Suntory Ltd | ヒトアミロイド関連蛋白モノクロ−ナル抗体 |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
CA1340802C (en) | 1987-08-15 | 1999-10-26 | Yasuyuki Takahashi | Senile amyloid precursor protein and an antibody specific for the same |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
WO1989006689A1 (en) | 1988-01-13 | 1989-07-27 | The Mclean Hospital Corporation | Genetic constructs containing the alzheimer brain amyloid gene |
AU3204689A (en) | 1988-02-10 | 1989-09-06 | Children's Medical Center Corporation | Amyloid protein precursors, genetic probes, antibodies, and methods of use |
US5134062A (en) | 1988-03-22 | 1992-07-28 | Cornell Research Foundation, Inc. | Diagnosis of neuronal disorders and screening potential therapeutic agents therefor |
US5015570A (en) | 1988-05-13 | 1991-05-14 | Molecular Therapeutics, Inc. | Molecular diagnosis of Alzheimer Disease |
US6287793B1 (en) | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
AU5525090A (en) | 1989-04-14 | 1990-11-16 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
US5234814A (en) | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
EP0411974A1 (de) | 1989-07-05 | 1991-02-06 | N.V. Innogenetics S.A. | Monoklonale Antikörper gegen neurofibrillisches Gewirrantigen |
EP0415801A1 (de) | 1989-07-05 | 1991-03-06 | N.V. Innogenetics S.A. | Monoklonale Antikörper gegen aktivierte Mikrogliazellen |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | タンパク質マイクロスフェア組成物 |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
AU7121191A (en) | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
DE4022247A1 (de) | 1990-07-12 | 1992-01-16 | Hoechst Ag | Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
ES2181673T3 (es) | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
EP0519596B1 (de) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JPH04342883A (ja) | 1991-05-17 | 1992-11-30 | Sanden Corp | 容量可変型斜板式圧縮機 |
JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU662178B2 (en) | 1991-10-25 | 1995-08-24 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau |
AU669493B2 (en) | 1991-11-12 | 1996-06-13 | University Of Melbourne, The | A method for assaying and treating Alzheimer's disease |
US20020009443A1 (en) | 1991-12-02 | 2002-01-24 | Vanitha Ramakrishman | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US20010029293A1 (en) | 1992-01-27 | 2001-10-11 | Icos Corporation | Icam-related protein |
US5538845A (en) | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5912120A (en) | 1992-04-09 | 1999-06-15 | The United States Of America As Represented By The Department Of Health And Human Services, | Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5455169A (en) | 1992-06-04 | 1995-10-03 | Alzheimer's Institute Of America, Inc. | Nucleic acids for diagnosing and modeling Alzheimer's disease |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
TW258789B (de) | 1992-09-28 | 1995-10-01 | Rohm & Haas | |
US5605811A (en) | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
US5891623A (en) | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
ZA938243B (en) | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン,インコーポレイティド | 万能dr−結合性ペプチドを用いる免疫応答の改変 |
CA2174501A1 (en) | 1993-10-20 | 1995-04-27 | Warren J. Strittmatter | Method of binding material to the .beta.-amyloid peptide |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995016787A1 (en) | 1993-12-13 | 1995-06-22 | The Uab Research Foundation | Diagnostic tests and reagents for detecting risk of alzheimer's disease and stroke |
US6620915B2 (en) | 1993-12-23 | 2003-09-16 | Icos Corporation | Monoclonal antibodies specific for integrin α-d subunit |
US6432404B1 (en) | 1993-12-23 | 2002-08-13 | Icos Corporation | Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies |
US6251395B1 (en) | 1993-12-23 | 2001-06-26 | W. Michael Gallatin | Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
JPH07238096A (ja) | 1994-02-25 | 1995-09-12 | S R L:Kk | 抗ポリユビキチン・モノクローナル抗体およびポリユビキチンの測定方法 |
US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6018021A (en) | 1994-10-19 | 2000-01-25 | The Research Foundation Of State University Of New York | Human transaldolase: an autoantigen with a function in metabolism |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
JPH10511957A (ja) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | 表面改質ナノ微粒子並びにその製造及び使用方法 |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
JP3663228B2 (ja) | 1995-03-14 | 2005-06-22 | 株式会社医学生物学研究所 | ニューロプシンに対する抗体 |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5705330A (en) | 1995-04-14 | 1998-01-06 | Abbott Laboratories | Chemiluminescent immunoassay for antibody detection |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
JP3392627B2 (ja) | 1995-04-17 | 2003-03-31 | 三洋電機株式会社 | 2次元映像を3次元映像に変換する方法 |
EP0826034A4 (de) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | Herstellung grosser genomischer dna-deletionen |
EP0822830B1 (de) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5712158A (en) | 1995-06-06 | 1998-01-27 | Warner-Lambert Company | Cell line for the rapid expression of functional calcium channels |
AU6255096A (en) | 1995-06-07 | 1996-12-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | Pegylated modified proteins |
US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
JP3081512B2 (ja) | 1995-06-21 | 2000-08-28 | 三洋電機株式会社 | 立体映像装置 |
JP3767755B2 (ja) | 1995-06-23 | 2006-04-19 | エーザイ株式会社 | 抗jcウイルス抗体 |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
EP1416280A3 (de) | 1995-09-14 | 2005-08-10 | The Regents of the University of California | Antikörper spezifisch für natives PrPsc |
FR2740454B1 (fr) | 1995-10-26 | 1997-11-21 | Rhone Poulenc Rorer Sa | Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes |
AUPN649395A0 (en) | 1995-11-10 | 1995-12-07 | Ramsay Health Care Pty Ltd | A method for diagnosing alzheimer's disease |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
KR19980702156A (ko) | 1995-12-12 | 1998-07-15 | 히라따 다다시 | 신규 dna, 신규 폴리펩티드 및 신규 항체 |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
ES2176523T3 (es) | 1996-01-19 | 2002-12-01 | Res Corp Technologies Inc | Procedimiento para la deteccion de la enfermedad de alzheimer. |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
EP0948536B1 (de) | 1996-01-30 | 2007-06-13 | The Scripps Research Institute | G-protein gekoppelter rezeptor mit vergrösserter, extrazellulärer domäne |
WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
WO1997046678A1 (en) | 1996-06-06 | 1997-12-11 | Bayer Corporation | Nucleic acids and polypeptides related to presenilin |
JPH109900A (ja) | 1996-06-21 | 1998-01-16 | Kanto Auto Works Ltd | メ−タ指針 |
WO1999009150A1 (en) | 1996-08-15 | 1999-02-25 | Bayer Corporation | Method of introducing modifications into a gene |
CA2183901A1 (en) | 1996-08-22 | 1998-02-23 | Johanna E. Bergmann | Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans |
US7521531B2 (en) | 1996-08-28 | 2009-04-21 | Immunomedics, Inc. | Methods for the purification of stable radioiodine conjugates |
JPH1075781A (ja) | 1996-08-30 | 1998-03-24 | Sumitomo Electric Ind Ltd | ヒトプロテアソームサブユニットp58蛋白質及びそれに特異的な抗体 |
EP0834561A1 (de) | 1996-09-27 | 1998-04-08 | Rijksuniversiteit te Leiden | Gen assoziiert mit Migräne bei Menschen |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
US5919687A (en) | 1996-12-24 | 1999-07-06 | John Hopkins University | Recombinant N-SMases and nucleic acids encoding same |
ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
KR100566859B1 (ko) | 1997-01-21 | 2006-04-03 | 제너럴 하스피톨 코포레이션 | Rna-단백질 융합물을 이용한 단백질의 선별 |
JPH10210982A (ja) | 1997-01-31 | 1998-08-11 | Fuji Yakuhin Kogyo Kk | 新規なタンパク質 |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US6413940B1 (en) | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
US7226730B1 (en) | 1997-02-26 | 2007-06-05 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease |
US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
CN1315473C (zh) | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
AU8755798A (en) | 1997-04-04 | 1998-11-13 | Biosite Diagnostics Incorporated | Polyvalent and polyclonal libraries |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
WO1998049286A2 (en) | 1997-05-01 | 1998-11-05 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP0981618B2 (de) | 1997-05-15 | 2011-08-24 | Genentech, Inc. | Anti-apo-2 antikörper |
NZ501424A (en) | 1997-07-21 | 2005-08-26 | Arpi Matossian Rogers | Ligands, including antibodies, showing reactivity against anti-TCR V-beta antibody |
IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
PT1049712E (pt) | 1997-08-14 | 2007-04-30 | Pasteur Institut | Proteínas híbridas da toxina do tétano que migram retrogradamente e trans - sinapticamente para o snc |
PT1007092E (pt) | 1997-08-26 | 2006-12-29 | Amgen Fremont Inc | Um processo para inibir a activação do complemento pela via alternativa |
US6666935B1 (en) | 1997-09-09 | 2003-12-23 | The Regents Of The University Of California | Sol-gel manufactured energetic materials |
FR2768346B1 (fr) | 1997-09-15 | 2002-04-19 | Fond Jean Dausset Ceph | Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic |
US20040185039A1 (en) | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
AU1197599A (en) | 1997-10-24 | 1999-05-17 | Cornel Research Foundation, Inc. | Detection of neurodegenerative diseases |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
DE1033998T1 (de) | 1997-12-03 | 2001-05-23 | Brigham And Women S Hospital B | Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer |
WO1999031239A1 (fr) | 1997-12-15 | 1999-06-24 | Kyowa Hakko Kogyo Co., Ltd. | PROTEINE Nap1 HUMAINE |
US6730778B2 (en) | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
US7189703B2 (en) | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
EP1054664B1 (de) | 1998-02-11 | 2012-08-08 | BHI Limited Partnership | Verfahren zur regulierung von macrophag-aktivierung |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US20050112543A1 (en) | 1998-03-11 | 2005-05-26 | The General Hospital Corporation | Method of screening for drugs useful in treating Alzheimer's disease |
US20050059802A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20050059591A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO1999058157A1 (en) | 1998-05-08 | 1999-11-18 | Cramer Donald V | Method for inhibiting antibody-mediated rejection of xenogeneic tissues |
NO314086B1 (no) | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
EP1077690A1 (de) | 1998-05-15 | 2001-02-28 | Neurochem, Inc. | Verwendung von amyloid-inhibitoren zur regulierung des neuronalen zelltodes |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
JP4637351B2 (ja) | 1998-06-01 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 神経変性疾患の処置法 |
JP2000050885A (ja) | 1998-06-02 | 2000-02-22 | Fuji Chemical Industries Ltd | カテプシンに対する抗体およびそれらの利用 |
AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
EP1092767B1 (de) | 1998-07-02 | 2006-10-11 | Fuso Pharmaceutical Industries, Ltd. | Serinprotease-spzifischer moniklonaler antikörper und seine verwendung |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US7038019B2 (en) | 1998-09-01 | 2006-05-02 | Genentech, Inc. | Antibodies to PRO1410 |
KR100640265B1 (ko) | 1998-09-17 | 2006-10-31 | 오츠카 세이야쿠 가부시키가이샤 | Ly6h 유전자 |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
AU5999199A (en) | 1998-09-29 | 2000-04-17 | Kyowa Hakko Kogyo Co. Ltd. | Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CA2353795A1 (en) | 1998-12-02 | 2000-06-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
EP1731913A3 (de) | 1998-12-02 | 2007-01-17 | The Trustees Of The University Of Pennsylvania | Verfahren und Zusammensetzungen zur Bestimmung des Lipidperoxidierungsgehaltes in oxidativen Stress-Syndromen und Krankheiten |
KR100664625B1 (ko) | 1998-12-14 | 2007-01-04 | 유니버시티 오브 마이애미 | 결합 조직 성장인자 단편, 그의 제조 방법 및 그의 용도 |
NZ512553A (en) | 1998-12-23 | 2004-02-27 | Pfizer | Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) |
DE19902550A1 (de) | 1999-01-22 | 2000-07-27 | Memorec Medical Molecular Rese | Aspartatprotease |
US20030185826A1 (en) | 1999-02-24 | 2003-10-02 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
TR200503572T2 (tr) | 1999-03-25 | 2006-04-21 | Knoll Gmbh & Co. Kg. | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
FR2791263B1 (fr) | 1999-03-26 | 2001-04-27 | Halina Zofia Malina | Preparations des medicaments bases sur une reponse immunitaire contre l'accumulation de proteines modifiees par l'acide xanthurenique |
EP2270148A3 (de) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur Kontrolle der Aktivität von immunologisch funktionellem Molekül |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20040002134A1 (en) | 1999-06-03 | 2004-01-01 | Curagen Corporation | Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
JP2000354487A (ja) | 1999-06-15 | 2000-12-26 | Takashi Muramatsu | ミッドカイン受容体 |
US20020002270A1 (en) | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
WO2000077178A1 (en) | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
DE60016242T2 (de) | 1999-09-01 | 2005-12-01 | Evotec Neurosciences Gmbh | Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration |
CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
US20040013647A1 (en) | 1999-09-03 | 2004-01-22 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating a plaque-forming disease |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
JP2001122900A (ja) | 1999-10-21 | 2001-05-08 | Yasukazu Tanuma | 抗−DNaseγ抗体並びにその製造及び使用 |
AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
EP1235587A2 (de) | 1999-11-29 | 2002-09-04 | Neurochem, Inc. | Impfstoffe zur vorbeugung und behandlung von alzheimer und amyloid verwandten krankheiten enthaltend peptide bestehend nur aus d-aminosäuren |
US20070135337A2 (en) | 1999-11-29 | 2007-06-14 | Neurochem (International) Limited | Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
PT1237930E (pt) | 1999-12-08 | 2007-02-28 | Intellect Neurosciences Inc | Péptidos beta amiloides quiméricos |
EP1752472A3 (de) | 1999-12-08 | 2007-04-25 | Intellect Neurosciences, Inc. | Schimärische Amyloid-beta-Peptide |
JP2001231578A (ja) | 1999-12-09 | 2001-08-28 | Kyowa Hakko Kogyo Co Ltd | Il−1ファミリーに属する蛋白質 |
MXPA02006196A (es) | 1999-12-23 | 2002-12-09 | Neurochem Inc | Compuestos y metodos para modular la angiopatia amiloide cerebral. |
US20030077757A1 (en) | 2000-01-11 | 2003-04-24 | Andrews William H. | Method of treating aging-related disorders |
WO2001054318A1 (en) | 2000-01-17 | 2001-07-26 | Corning O.T.I. S.P.A. | Attenuator integrated with modulator and transmitting module for wdm system using the same |
AU2001229592A1 (en) * | 2000-01-21 | 2001-07-31 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
US6806254B2 (en) | 2000-02-03 | 2004-10-19 | Nuvelo, Inc. | Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
ATE306933T1 (de) | 2000-02-21 | 2005-11-15 | Pharmexa As | Verfahren zur herabregulierung von amyloid |
MXPA02007796A (es) | 2000-02-21 | 2003-12-08 | Pharmexa As | Metodo novedoso para la disminucion de cuerpos amiloides. |
EP1257584B2 (de) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanisierte antikörper, die amyloid beta peptid sequestrieren |
EP1130032A1 (de) | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Einzelkette-Antikörper die den menschlichen vaskulären endothelialen Wachstumsfaktorrezeptor-2 (VEGFR-2/KDR) erkennen |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
WO2001071351A1 (en) | 2000-03-22 | 2001-09-27 | The General Hospital Corporation | Method for treatment of neurodegenerative diseases |
WO2001075165A2 (en) | 2000-03-30 | 2001-10-11 | Elan Pharmaceuticals, Inc. | Screening markers and methods for neurodegenerative disorders |
JP2004505609A (ja) | 2000-04-03 | 2004-02-26 | オックスフォード グリコサイエンシズ(ユーケー) リミテッド | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 |
US7371365B2 (en) | 2000-04-04 | 2008-05-13 | Mayo Foundation For Medical Education And Research | Methods for detecting parenchymal plaques in vivo |
AUPQ712000A0 (en) | 2000-04-27 | 2000-05-18 | Medvet Science Pty. Ltd. | Antigenic peptide fragments of VapA protein, and uses thereof |
US20080009467A1 (en) | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
EP1278778A2 (de) | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modifizierte peptide, die eine fc-domäne behalten, als therapeutische agenzien |
US6713450B2 (en) | 2000-05-22 | 2004-03-30 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits |
AU2001271422B2 (en) | 2000-06-22 | 2005-12-22 | Genentech, Inc. | Agonist anti-trk-C monoclonal antibodies |
JP4252195B2 (ja) | 2000-06-27 | 2009-04-08 | 新日本無線株式会社 | 高周波線路の変換器 |
EP1296705B1 (de) | 2000-06-28 | 2012-06-13 | Prana Biotechnology Limited | Amyloid Beta Oligomere zur Behandlung, Linderung oder Vorbeugung der Alzheimers Krankheit |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
AU2001269127A1 (en) | 2000-07-06 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | A novel app mutation associated with an unusual alzheimer's disease pathology |
JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
AU2007200047B2 (en) | 2000-07-07 | 2009-11-26 | Bioarctic Neuroscience Ab | Prevention and treatment of Alzheimer's disease |
US6524819B1 (en) | 2000-07-11 | 2003-02-25 | Incyte Genomics, Inc. | Down syndrome critical region 1-like proteins |
EP1172378A1 (de) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Menschlische beta-Amyloid Antikörpern und ihre Verwendung zur Behandlung von Alzheimerscher Krankheit |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
JP2002040023A (ja) | 2000-07-28 | 2002-02-06 | Mitsubishi Chemicals Corp | アルツハイマー病の検出方法 |
US20070009931A1 (en) | 2000-08-04 | 2007-01-11 | Kirsch Wolff M | Negative correlation between IRP-2 and Transferrin receptor expression as a diagnostic of Alzheimer's disease |
US7067133B2 (en) | 2000-09-06 | 2006-06-27 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
GB0024446D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Protein |
IT1319277B1 (it) | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer. |
CA2360219A1 (en) | 2000-10-27 | 2002-04-27 | Mount Sinai Hospital | Method for detecting alzheimer's disease |
WO2002036614A2 (en) | 2000-11-01 | 2002-05-10 | Insight Biotechnology Limited | Peptides for use in the treatment of alzheimer's disease |
DE10055703A1 (de) | 2000-11-02 | 2002-05-08 | Peter F Pascoe | Verhinderung der Zellzerstörung und Beseitigung sklrotischer Amyloide verursacht durch organspezifische Antikörperaggregate |
WO2002094870A2 (en) | 2000-11-02 | 2002-11-28 | Curagen Corporation | Proteins and nucleic acids encoding same |
EP1341548A4 (de) | 2000-11-03 | 2006-06-14 | Massachusetts Inst Technology | VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD |
US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
PT1346041E (pt) | 2000-11-27 | 2007-06-05 | Praecis Pharm Inc | Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica. |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
GB0100110D0 (en) | 2001-01-04 | 2001-02-14 | Univ Leeds | Modulation of calcium channel activity |
DE10101430B4 (de) | 2001-01-13 | 2008-10-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Lösliche cyclische Analoga zur Modulation der Amyloidogenese |
US20020132758A1 (en) | 2001-01-18 | 2002-09-19 | Shell John W. | Method for identifying compounds to treat medical pathologies associated with molecular crystallization |
US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US20040191264A1 (en) | 2001-02-19 | 2004-09-30 | Nielsen Klaus Gregorius | Synthetic vaccine agents |
JP4659236B2 (ja) | 2001-03-01 | 2011-03-30 | 大塚製薬株式会社 | 細胞傷害活性の測定法 |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
FR2822238B1 (fr) | 2001-03-16 | 2003-08-29 | Gemac | Methode et trousse pour le suivi des maladies neurodegeneratives |
DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
EP1383533A4 (de) | 2001-04-23 | 2006-11-02 | Curagen Corp | Proteine und diese kodierende nukleinsäuren |
US6451547B1 (en) | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
EP2165714B1 (de) | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanisierte Antikörper die das Beta-Amyloid Peptid erkennen |
DE60229051D1 (de) | 2001-04-30 | 2008-11-06 | Lilly Co Eli | Humanisierte antikörper |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
CA2448142A1 (en) | 2001-05-22 | 2002-11-28 | Merck & Co., Inc. | Beta-secretase substrates and uses thereof |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
DE50103881D1 (de) | 2001-06-12 | 2004-11-04 | Wiltfang Jens | Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
US7094884B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them |
US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
CN1396183A (zh) | 2001-07-13 | 2003-02-12 | 张小如 | 降低脑内与老年痴呆有关的淀粉样变纤维的融合人抗体 |
WO2003008626A2 (en) | 2001-07-20 | 2003-01-30 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
JP4729717B2 (ja) | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA |
JP4320694B2 (ja) | 2001-08-08 | 2009-08-26 | 株式会社オーク製作所 | 多重露光描画装置および多重露光式描画方法 |
AU2002324787A1 (en) | 2001-08-10 | 2003-02-24 | University Of South Florida | Modulation of angiogenesis by a-beta peptides |
WO2003016467A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
AU2002324468A1 (en) | 2001-08-17 | 2003-03-03 | Eli Lilly And Company | Rapid improvement of cognition in conditions related to abeta |
ES2295401T3 (es) | 2001-08-17 | 2008-04-16 | Washington University | Metodo de ensayo para la enfermedad de alzheimer. |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US7771722B2 (en) | 2001-08-17 | 2010-08-10 | Eli Lilly And Company | Assay method for alzheimer's disease |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
JP2003284574A (ja) | 2001-10-03 | 2003-10-07 | Pfizer Prod Inc | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 |
JP4153873B2 (ja) | 2001-10-04 | 2008-09-24 | 株式会社 免疫生物研究所 | アルツハイマー危険因子の検出試薬および検出用キットならびにこれらを用いるアルツハイマー危険因子の検出方法 |
JP2005508338A (ja) | 2001-10-04 | 2005-03-31 | プロテイン セラピューティクス、インク. | 免疫性疾患を処置するためのガンマグロブリンの使用 |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
CN100488982C (zh) | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
US7026129B2 (en) | 2001-11-23 | 2006-04-11 | Syn X Pharma, Inc. | IG lambda biopolymer markers predictive of Alzheimers disease |
US7179606B2 (en) | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
DE10158180A1 (de) | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
WO2003046012A1 (en) | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
JP2005521645A (ja) | 2001-12-04 | 2005-07-21 | ベン グリオン ユニバーシティ オブ ザ ネジェブ リサーチ アンド ディベラップメント オーソリティ | 器官特異的薬物ターゲティング用両親媒性化合物及び小胞/リポソーム |
US20050227941A1 (en) | 2001-12-17 | 2005-10-13 | Karen Duff | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases |
WO2005016236A2 (en) | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US20070128191A1 (en) | 2001-12-26 | 2007-06-07 | Universidad De Zaragoza | Polyclonal antibodies, preparation method thereof and use of same |
US7781396B2 (en) | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20050153381A1 (en) | 2002-02-14 | 2005-07-14 | Marusich Michael F. | Immunocapture of mitochondrial protein complexes |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
EP1487879B1 (de) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Punktmutationen bei bispezifischen antikörpern zur verbesserung der clearance-rate |
WO2003074004A2 (en) | 2002-03-01 | 2003-09-12 | Szu-Yi Chou | Method of producing antigens |
US7494655B2 (en) | 2002-03-05 | 2009-02-24 | Ramot At Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
CN100360555C (zh) | 2002-04-19 | 2008-01-09 | 多伦多大学董事局 | 治疗阿尔茨海默氏病的免疫学方法及组合物 |
WO2003091734A1 (en) | 2002-04-24 | 2003-11-06 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases |
EP1501531B1 (de) | 2002-04-25 | 2009-01-07 | Eli Lilly And Company | Verfahren zur behandlung von angststörungen bei älteren personen |
US20060257420A1 (en) | 2002-04-26 | 2006-11-16 | Cel-Sci Corporation | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions |
DE10221052A1 (de) | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
AU2003243058A1 (en) | 2002-05-27 | 2003-12-12 | Bioceros B.V. | Methods for using the cd163 pathway for modulating an immune response |
EP1521614A2 (de) | 2002-06-14 | 2005-04-13 | Brainsgate Ltd. | Methoden und systeme zur handhabung der alzheimer krankheit |
EP1514118A2 (de) | 2002-06-20 | 2005-03-16 | EVOTEC Neurosciences GmbH | Diagnostische und therapeutische verwendung von ras-gtpase-aktivierendem sh3-bindendem protein 2 (g3bp2) für neurodegenerative erkrankungen |
WO2004003563A2 (en) | 2002-06-27 | 2004-01-08 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
CN100572392C (zh) | 2002-07-12 | 2009-12-23 | 阿克松神经科学研究和发展股份有限公司 | 截短tau蛋白 |
EP1575529A4 (de) | 2002-07-17 | 2007-08-08 | Intellect Neurosciences Inc | Peptide und verfahren zur untersuchung von immunogenen peptid-vakzinen gegen alzheimer-krankheit |
AU2003281615A1 (en) | 2002-07-18 | 2004-02-09 | Osaka Industrial Promotion Organization | NOVEL Notch-ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS USING THE SAME |
PL213925B1 (pl) | 2002-07-19 | 2013-05-31 | Abbott Biotech Ltd | Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw |
DE60336902D1 (de) | 2002-07-19 | 2011-06-09 | Cytos Biotechnology Ag | Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays |
US7250551B2 (en) | 2002-07-24 | 2007-07-31 | President And Fellows Of Harvard College | Transgenic mice expressing inducible human p25 |
WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
SE0202880D0 (sv) | 2002-07-26 | 2002-09-30 | Wieslab Ab | Complement system deficiency assay |
DE60326153D1 (de) | 2002-07-30 | 2009-03-26 | David Gladstone Inst | Verfahren zur diagnose von morbus alzheimer |
US20040138296A1 (en) | 2002-08-12 | 2004-07-15 | Pharmacia Corporation | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease |
US7252953B2 (en) | 2002-08-13 | 2007-08-07 | United States Of America Department Of Veterans Affairs | Method of detecting and preventing Alzheimer's disease, particularly at prodromal and early stages |
WO2004016655A1 (ja) | 2002-08-14 | 2004-02-26 | Mitsubishi Chemical Corporation | 中枢性タウ蛋白質特異的抗体 |
WO2004018997A2 (en) | 2002-08-20 | 2004-03-04 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
AU2003266302A1 (en) | 2002-08-23 | 2004-03-11 | Proteosys Ag | Method for the diagnosis of alzheimer disease |
CA2498407A1 (en) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
US20070010657A1 (en) | 2002-09-13 | 2007-01-11 | Rainer Klocke | Cytoplasmic dynein heavy chain 1 genes, expression products, non-human animal model uses in human neurological diseases |
US7238488B2 (en) | 2002-09-13 | 2007-07-03 | Grace Maresh | Therapeutic and diagnostic applications of perlecan domain I splice variants |
EP1558268A4 (de) | 2002-09-17 | 2008-09-17 | Univ New York | Verfahren zur behandlung von altersassoziierten gedächtnisstörungen (aami), leichter kognitiver beeinträchtigung (mci) und demenzen mit zellzyklushemmern |
JP4242128B2 (ja) | 2002-09-18 | 2009-03-18 | 武田薬品工業株式会社 | 脳アミロイドーシス予防・治療薬のスクリーニング方法 |
WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US20070213512A1 (en) | 2002-10-01 | 2007-09-13 | Krafft Grant A | Amyloid beta peptide analogs and assemblies thereof |
CA2501091A1 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
AU2003272925A1 (en) | 2002-10-04 | 2004-04-23 | Techno Network Shikoku Co., Ltd. | Monoclonal antibody against subtilisin-like proprotein convertase pace4 and utilization thereof |
AU2003282575A1 (en) | 2002-10-09 | 2004-05-04 | Activx Biosciences, Inc. | Activity-based probes, and methods of their preparation and use |
KR20050071564A (ko) | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
WO2004038411A2 (en) | 2002-10-24 | 2004-05-06 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
AU2003295411A1 (en) | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
WO2004045525A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
CN100450551C (zh) | 2002-11-29 | 2009-01-14 | 中国医学科学院基础医学研究所 | 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途 |
EP1578947A4 (de) | 2002-12-02 | 2006-12-06 | Abgenix Inc | Gegen phospholipase a2 gerichtete antikörper und verwendungen davon |
AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
WO2004058258A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
WO2004065419A1 (ja) | 2003-01-22 | 2004-08-05 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
EP2270051B1 (de) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antikörper spezifisch gegen humanes PD-1 und CD3 |
WO2004065569A2 (en) | 2003-01-23 | 2004-08-05 | The Regents Of The University Of California | Multi-functional antibodies |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
RU2390350C2 (ru) | 2003-02-01 | 2010-05-27 | Ньюралаб Лимитед | Активная иммунизация для создания антител к растворимому а-бета |
US7223393B2 (en) | 2003-02-07 | 2007-05-29 | Pdl Biopharma, Inc | Amphiregulin antibodies and their use to treat cancer and psoriasis |
DE602004027348D1 (de) | 2003-02-10 | 2010-07-08 | Applied Molecular Evolution | Abeta-bindende moleküle |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
WO2004074837A1 (en) | 2003-02-24 | 2004-09-02 | Digitalbiotech Co., Ltd. | Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same |
US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
EP2405015B1 (de) | 2003-03-05 | 2016-01-06 | Halozyme, Inc. | Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzungen, die dieses umfassen |
WO2004085712A2 (en) | 2003-03-24 | 2004-10-07 | Penn State Research Foundation | Multi-functional polymeric materials and their uses |
JP4939929B2 (ja) | 2003-03-26 | 2012-05-30 | ポール,サッドヒル | タンパク質分解抗体および共有結合抗体 |
WO2004087733A2 (en) | 2003-03-28 | 2004-10-14 | New York University | Prevention and treatment of alzheimer amyloid deposition |
CN1189210C (zh) | 2003-03-28 | 2005-02-16 | 万选才 | Cb与生物活性多肽的偶联物及其医药用途 |
AU2004274390A1 (en) | 2003-03-28 | 2005-03-31 | Jacqueline M. Benson | Anti-amyloid antibodies, compositions, methods and uses |
CA2522067C (en) | 2003-04-09 | 2010-07-06 | Canadian Blood Services | Detection, characterization and treatment of viral infection and methods thereof |
EP1469312A1 (de) | 2003-04-18 | 2004-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnose der Alzheimer Krankheit |
WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
US20040223912A1 (en) | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
ES2246177B1 (es) | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
EP1480041A1 (de) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer |
WO2005018536A2 (en) | 2003-05-23 | 2005-03-03 | Human Genome Sciences, Inc. | Agonist antibodies that specifically bind the glucagon like peptide-1 receptor |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2007535905A (ja) | 2003-06-06 | 2007-12-13 | オンコマックス アクイジション コーポレイション | 癌関連抗原sm5−1の特異抗体およびその用途 |
US7892751B2 (en) | 2003-06-09 | 2011-02-22 | Redox-Reactive Reagents Llc | Method of detecting or diagnosing of a neurodegenerative disease or condition |
JP4888876B2 (ja) | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
RU2006101702A (ru) | 2003-06-23 | 2006-09-10 | Дженетикс Инститьют, Ллс (Us) | Антитела против интерлейкина-22 и их применения |
EP1638517A4 (de) | 2003-06-30 | 2010-01-06 | Univ Tel Aviv Future Tech Dev | Dagegen gerichtete peptid-antikörper und diese verwendende verfahren zur diagnose und behanldung von amyloid-assoziierten erkrankungen |
US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
US7579375B2 (en) | 2003-07-15 | 2009-08-25 | Ono Pharmaceutical Co., Ltd. | Branched carboxylic acid compound and use thereof |
WO2005012330A2 (en) | 2003-07-30 | 2005-02-10 | Brigham And Women's Hospital, Inc. | AMYLOID β-PEPTIDE AND METHODS OF USE |
US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
CA2534898A1 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
JP4239750B2 (ja) | 2003-08-13 | 2009-03-18 | セイコーエプソン株式会社 | マイクロレンズ及びマイクロレンズの製造方法、光学装置、光伝送装置、レーザプリンタ用ヘッド、並びにレーザプリンタ |
WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
JP2007527865A (ja) | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
EP1516930A1 (de) | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Zelluläres Model der Tauopathien zur "Lead"-Identifikation und zur Entdeckung von Wirkstoffen |
WO2005027965A1 (en) | 2003-09-24 | 2005-03-31 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
ATE509034T1 (de) | 2003-10-07 | 2011-05-15 | Yeda Res & Dev | Antikörper gegen nik, deren herstellung und verwendung |
CA2542084A1 (en) | 2003-10-14 | 2005-04-28 | University Of South Florida | A method for the separation anti-amyloid beta antibody with amyloid beta peptide |
DE602004022575D1 (de) | 2003-10-15 | 2009-09-24 | Sekisui Medical Co Ltd | Verfahren zum selektiven testen von adiponectinmultimeren |
CA2543058A1 (en) | 2003-10-20 | 2005-05-12 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing mutant a.beta.42 |
EP1680447A2 (de) | 2003-10-24 | 2006-07-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Orthogonale genschalter |
PL2149585T3 (pl) | 2003-11-04 | 2014-01-31 | Novartis Vaccines & Diagnostics Inc | Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40 |
WO2005044847A1 (ja) | 2003-11-05 | 2005-05-19 | Toshiharu Suzuki | アルツハイマー病のマーカーペプチド |
JP4796967B2 (ja) | 2003-11-07 | 2011-10-19 | ヴァーミリオン インコーポレイテッド | アルツハイマー病のためのバイオマーカー |
WO2005046605A2 (en) | 2003-11-07 | 2005-05-26 | University Of Rochester | Compositions and methods of treating neurological diseases |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
UY28641A1 (es) | 2003-11-28 | 2005-06-30 | Astrazeneca Ab | Anticuerpos |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
CN102838675B (zh) | 2003-12-10 | 2014-07-30 | 梅达雷克斯有限责任公司 | Ip-10抗体及其用途 |
KR101157694B1 (ko) | 2003-12-17 | 2012-06-20 | 와이어쓰 엘엘씨 | 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
MY144612A (en) | 2003-12-22 | 2011-10-14 | Glaxo Group Ltd | Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
WO2005070965A2 (en) | 2004-01-21 | 2005-08-04 | Five Prime Therapeutics, Inc. | Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases |
US20070172496A1 (en) | 2004-01-28 | 2007-07-26 | Curix Aps | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
JP4824547B2 (ja) | 2004-02-20 | 2011-11-30 | インテレクト ニュウロサイエンシス,インク. | モノクローナル抗体およびその利用 |
UA93181C2 (ru) | 2004-02-23 | 2011-01-25 | Эли Лилли Энд Компани | СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ |
WO2005105841A2 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
WO2005090971A1 (en) | 2004-03-18 | 2005-09-29 | Applied Research Systems Ars Holding N.V. | Anti-lipid rafts antibodies |
CN1314805C (zh) | 2004-03-26 | 2007-05-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种新型促细胞凋亡素(apo)及其抗体,制备及用途 |
PE20060287A1 (es) | 2004-03-30 | 2006-05-16 | Glaxo Group Ltd | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM |
CA2561532A1 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds |
US20060099211A1 (en) | 2004-04-12 | 2006-05-11 | Carmen Monthe | Safer, more potent human immunoglobulin preparations for treating Alzheimer's disease |
JP2007532649A (ja) | 2004-04-15 | 2007-11-15 | サマリタン,ファーマスーティカルス,インク. | (4−アルキルピペラジニル)(フェニル)メタノン |
AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
WO2005105998A1 (ja) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
EP1755644A2 (de) | 2004-05-14 | 2007-02-28 | Northwestern University | Zubereitung enthaltend addlrezeptor syngap |
GR1005016B (el) | 2004-05-14 | 2005-10-11 | BIOMENTIKA@ΛΑΙΦ@ΣΑΙΕΝΣΙΣ@ΑΝΩΝΥΜΗ@ΕΤΑΙΡΕΙΑ@ΦΑΡΜΑΚΕΥΑΤΙΚΩΝ@ΠΡΟΙΟΝΤΩΝ@(συμμετέχει@σε@ποσοστό@50%)@Α | ΑΝΑΠΤΥΞΗ ΑΝΤΙΣΩΜΑΤΩΝ IgG KAI IgY ΕΝΑΝΤΙΟΝ ΕΙΔΙΚΟΥ ΣΥΝΘΕΤΙΚΟΥ ΕΠΙΤΟΠΙΚΟΥ ΠΑΡΑΓΩΓΟΥ ΤΗΣ HUMANIN (24-ΠΕΠΤΙΔΙΟΥ ΣΧΕΤΙΖΟΜΕΝΟΥ ΜΕ ΤΗ ΝΟΣΟ ALZHEIMER) ΙΚΑΝΩΝ ΝΑ ΑΝΙΧΝΕΥΟΥΝ ΤΟ ΒΙΟΔΡΑΣΤΙΚΟ 24-ΠΕΠΤΙΔΙΟ. |
ATE476993T1 (de) | 2004-06-07 | 2010-08-15 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US20050276806A1 (en) | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of autism |
WO2006033688A2 (en) | 2004-06-18 | 2006-03-30 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
CA2572602A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta) |
WO2006005588A1 (en) | 2004-07-12 | 2006-01-19 | Geneprot, Inc. | Polypeptide species useful for the treatment of neurological disorders |
CN1721437A (zh) | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
US20090156471A1 (en) | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US7955812B2 (en) | 2004-07-19 | 2011-06-07 | The General Hospital Corporation | Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked β-amyloid oligomers |
US7652003B2 (en) | 2004-07-28 | 2010-01-26 | Schering-Plough Corporation | Macrocyclic β-secretase inhibitors |
US7927594B2 (en) | 2004-07-30 | 2011-04-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide |
JP2008509172A (ja) | 2004-08-09 | 2008-03-27 | セルゾーム アーゲー | Degsインヒビターの使用による神経変性疾患の治療 |
EP1776591B1 (de) | 2004-08-11 | 2013-10-16 | Evotec International GmbH | Diagnostische und therapeutische verwendung einer plasmamembran-atpase |
CN101080421A (zh) | 2004-08-11 | 2007-11-28 | 三菱化学株式会社 | 抗体以及其利用 |
DE102004039326A1 (de) | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US20060246075A1 (en) | 2004-09-29 | 2006-11-02 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
WO2006037604A1 (en) | 2004-10-01 | 2006-04-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
WO2006039327A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve |
US7807804B2 (en) | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
AU2005290401A1 (en) | 2004-10-06 | 2006-04-13 | Hiroshi Mori | Mutated amyloid protein |
EP1814917A2 (de) | 2004-10-13 | 2007-08-08 | Ablynx N.V. | Anti-amyloid-beta-antikörper aus kameliden und diese enthaltende polypeptide für die behandlung und diagnose degenerativer nervenerkrankungen wie etwa morbus alzheimer |
WO2006047254A1 (en) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
CA2584859C (en) | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
US20060160161A1 (en) | 2004-10-26 | 2006-07-20 | Elan Pharmaceuticals, Inc. | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
CN101048662A (zh) | 2004-10-28 | 2007-10-03 | 三光纯药株式会社 | 阿尔茨海默氏病的检验方法及诊断试剂 |
WO2006050041A2 (en) | 2004-10-28 | 2006-05-11 | Ramot At Tel Aviv University Ltd. | Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
JP2008519284A (ja) | 2004-11-08 | 2008-06-05 | ナノバック ファーマシューティカルズ, インコーポレイテッド | タンパク質−ヒドロキシアパタイト複合体に関する方法および組成物、ならびにカルシウム結合タンパク質−ヒドロキシアパタイト複合体に対する抗体の検出のための新規インビトロ試験を含む免疫系を試験および調節することにおけるそれらの適用 |
US7709208B2 (en) | 2004-11-08 | 2010-05-04 | New York University | Methods for diagnosis of major depressive disorder |
CN1772766A (zh) | 2004-11-12 | 2006-05-17 | 中国科学院上海生命科学研究院 | 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 |
US20060189582A1 (en) | 2004-11-17 | 2006-08-24 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
AR051800A1 (es) | 2004-12-15 | 2007-02-07 | Wyeth Corp | Anticuerpos a beta usados en mejorar la cognicion |
US7625560B2 (en) | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
JP2006166879A (ja) | 2004-12-20 | 2006-06-29 | Japan Health Science Foundation | Ab−dip、並びにアルツハイマー病の予防及び治療剤 |
US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
WO2006067792A2 (en) | 2004-12-22 | 2006-06-29 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Aldolase autoantigens useful in diagnosis and treatment of alzheimer's disease |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1676859A1 (de) | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Immunogene Zusammensetzungen aus zyklischen Peptiden abgegleitet vom beta-Amyloid Peptid |
JP2008527005A (ja) | 2005-01-14 | 2008-07-24 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法 |
AU2006208226A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
JP2006213621A (ja) | 2005-02-02 | 2006-08-17 | Japan Health Science Foundation | Adoplinタンパク質、およびその利用 |
US20070082350A1 (en) | 2005-02-09 | 2007-04-12 | Philip Landfield | Assay and method for diagnosing and treating alzheimer's disease |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
GB0503434D0 (en) | 2005-02-18 | 2005-03-30 | Senexis Ltd | Amyloid-binding peptides, analogues and uses thereof |
WO2006094192A2 (en) | 2005-03-03 | 2006-09-08 | Immunomedics, Inc. | Humanized l243 antibodies |
WO2006096653A2 (en) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
EP1861422B1 (de) | 2005-03-05 | 2010-02-24 | Abbott GmbH & Co. KG | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper |
WO2006096529A2 (en) | 2005-03-07 | 2006-09-14 | Novartis Ag | Genes involved in neurodegenerative conditions |
ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
WO2006099543A2 (en) | 2005-03-15 | 2006-09-21 | The Regents Of The University Of California | Methods for assessing antibody-mediated cytotoxicity |
WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
JP2006265189A (ja) | 2005-03-24 | 2006-10-05 | Kyoto Univ | βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法 |
ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
WO2006110748A2 (en) | 2005-04-08 | 2006-10-19 | The University Of Maryland, Baltimore | Response gene to complement 32 (rgc-32) in disease |
US20060241038A1 (en) | 2005-04-20 | 2006-10-26 | Eisai Co., Ltd. | Therapeutic agent for Abeta related disorders |
BRPI0612972A2 (pt) | 2005-04-22 | 2010-12-14 | Genentech Inc | mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20 |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
WO2006119449A2 (en) | 2005-05-04 | 2006-11-09 | Vectorlogics, Inc. | Modified adenovirus containing a stabilized antibody |
RU2406529C2 (ru) | 2005-05-05 | 2010-12-20 | Мерк Шарп Энд Домэ Корп. | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера |
EP1888783B1 (de) | 2005-05-27 | 2011-10-26 | EVOTEC Neurosciences GmbH | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit |
EP1907566A4 (de) | 2005-05-27 | 2008-12-10 | Memory Pharm Corp | Vektoren für transgenes morbus-alzheimer-mausmodell und verwendungen davon |
KR20080032070A (ko) | 2005-06-06 | 2008-04-14 | 와이어쓰 | 항-TrkB 모노클로날 항체 및 이의 용도 |
WO2006138553A2 (en) | 2005-06-17 | 2006-12-28 | Wyeth | Methods of purifying fc region containing proteins |
EP1921137A4 (de) | 2005-06-21 | 2011-01-26 | Med & Biological Lab Co Ltd | Antikörper mit hemmwirkung auf die amyloidfibrillenbildung |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
BRPI0613387A2 (pt) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone |
US20090297534A1 (en) | 2005-07-13 | 2009-12-03 | Sudhir Paul | Catalytic Immunoglobulins BBK32 and Uses Therefor |
WO2007011834A2 (en) | 2005-07-15 | 2007-01-25 | The Regents Of The University Of California | Compounds and method for the diagnosis and treatment of amyloid associated diseases |
AU2006279896A1 (en) | 2005-08-10 | 2007-02-22 | Oklahoma Medical Research Foundation | Truncated memapsin 2 for use for treating Alzheimer's disease |
AU2006277785B2 (en) | 2005-08-11 | 2012-07-12 | Matossian-Rogers Arpi | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP2007077103A (ja) | 2005-09-16 | 2007-03-29 | Yokohama City Univ | アルツハイマー病の予防又は治療剤 |
WO2007040437A1 (en) | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Fusion proteins having a modulated half-life in plasma |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
CA2626356C (en) | 2005-10-21 | 2017-08-22 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
JP5289963B2 (ja) | 2005-10-21 | 2013-09-11 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗addlモノクローナル抗体およびその使用 |
US20070092508A1 (en) | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
KR101395005B1 (ko) | 2005-11-01 | 2014-05-21 | 조마 테크놀로지 리미티드 | 항cd40 항체의 용도 |
WO2007059135A2 (en) | 2005-11-10 | 2007-05-24 | Satoris, Inc. | Methods of treating alzheimer's disease |
US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
US20080014596A1 (en) | 2005-11-16 | 2008-01-17 | Jasna Jerecic | ADDL Binding to Hippocampal Neurons |
AU2006318537A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of Alzheimer's and related diseases |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
EP1963363A2 (de) | 2005-11-30 | 2008-09-03 | Abbott Laboratories | Verfahren zur herstellung rekombinanter formen von humanem beta-amyloid-protein und verwendung dieser proteine |
KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007067512A2 (en) | 2005-12-08 | 2007-06-14 | Merck & Co., Inc. | Method for identifying modulators of adprh useful for treating alzheimer's disease |
PE20100748A1 (es) | 2005-12-12 | 2010-11-12 | Hoffmann La Roche | Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
KR101591223B1 (ko) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
EP2380588B1 (de) | 2005-12-12 | 2015-08-05 | AC Immune S.A. | Therapeutischer Impfstoff |
ES2535856T3 (es) | 2005-12-15 | 2015-05-18 | Genentech, Inc. | Métodos y composiciones para dirigirse a la poliubiquitina |
US20080058276A1 (en) | 2006-01-13 | 2008-03-06 | Cornell Research Foundation, Inc. | Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein |
EP1811304A1 (de) | 2006-01-18 | 2007-07-25 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Große Aß-Peptid-bindende Partikel (LAPS) bei der Diagnose und Behandlung von Alzheimer-Demenz |
CN1329413C (zh) | 2006-01-23 | 2007-08-01 | 南京医科大学 | 一种治疗或预防老年性痴呆的抗体及其表达载体和在制药中的应用 |
EP1981540B1 (de) | 2006-01-30 | 2013-03-20 | Grifols Therapeutics Inc. | Verfahren zur behandlung und prophylaxe von mit amyloidablagerung assoziierten erkrankungen mittels igm |
GB0601976D0 (en) | 2006-02-01 | 2006-03-15 | Merck Sharp & Dohme | Proteins |
JP5211321B2 (ja) | 2006-02-02 | 2013-06-12 | 国立大学法人名古屋大学 | 神経細胞の細胞死阻害剤及びスクリーニング方法 |
JP2009533016A (ja) | 2006-02-06 | 2009-09-17 | イーラン ファーマスーティカルズ、インコーポレイテッド | プレセニリン1特異的阻害剤及びそれらの使用 |
AU2007213655A1 (en) | 2006-02-09 | 2007-08-16 | Novartis Ag | Antibodies against secreted fri zzled related protein-4 (SFRP-4 ) |
EP1991252A2 (de) | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Behandlung von alzheimer mit hemmern der apoe-bindung am apoe-rezeptor |
US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
EP1992639A4 (de) | 2006-02-22 | 2009-08-26 | Hayashibara Biochem Lab | Peptidimpfstoff zur induktion der produktion eines antiamyloidpeptidantikörpers |
EA014531B1 (ru) | 2006-02-24 | 2010-12-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Антиамилоидные иммуногенные композиции, способы и применения |
WO2007103788A2 (en) | 2006-03-02 | 2007-09-13 | The Board Of Trustees Of The University Of Illinois | Yeast reporter system based on fusion proteins of sup35p |
CA2642848C (en) | 2006-03-03 | 2016-07-12 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
WO2007109107A2 (en) | 2006-03-17 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Atf4 as a therapeutic target in alzheimers disease and other neurological disorders |
JP2009530423A (ja) | 2006-03-21 | 2009-08-27 | ワイス | アミロイド生成性疾患を予防および処置するための方法 |
US20100029654A1 (en) | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
CA2541522A1 (en) | 2006-03-28 | 2007-09-28 | E. Rick Preddie | A double elisa for alzheimer's disease (ad) with applications for therapeutic vaccines to stop the disease |
ES2338179T3 (es) | 2006-03-30 | 2010-05-04 | Glaxo Group Limited | Anticuerpos contra el peptido beta-amiloide. |
FR2899107B1 (fr) | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
EP2005174A4 (de) | 2006-03-31 | 2009-04-15 | Univ California | Verfahren und zusammensetzungen zur behandlung neurodegenerativer erkrankungen und morbus alzheimer sowie zur verbesserung des normalen gedächtnisses |
JP4790013B2 (ja) | 2006-04-13 | 2011-10-12 | エーディア株式会社 | β−アミロイドの血中分解速度測定によるアルツハイマー病の検定に用いられる方法及び診断試薬 |
CA2649359A1 (en) | 2006-04-21 | 2007-11-01 | Peoplebio, Inc. | Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides through three-dimensional interactions |
CN101058608B (zh) | 2006-04-21 | 2011-02-23 | 杜如昱 | 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途 |
WO2007129457A1 (ja) | 2006-04-25 | 2007-11-15 | The University Of Tokyo | アルツハイマー病および癌の治療薬 |
US20070259831A1 (en) | 2006-04-27 | 2007-11-08 | Carlezon William A Jr | Treatment and screening methods for promoting neurogenesis |
GB0608386D0 (en) | 2006-04-27 | 2006-06-07 | Senexis Ltd | Compounds |
EP2015751A2 (de) | 2006-04-28 | 2009-01-21 | Northwestern University | Salze aus pyridazinverbindungen |
JP2007300856A (ja) | 2006-05-11 | 2007-11-22 | Hiroshi Mori | アミロイドタンパク質模倣物 |
US20070292895A1 (en) | 2006-05-19 | 2007-12-20 | Xiao-Ping Shi | Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts |
JP2009538924A (ja) | 2006-06-01 | 2009-11-12 | エラン ファーマシューティカルズ,インコーポレイテッド | Appの神経活性断片 |
JP4933159B2 (ja) | 2006-06-02 | 2012-05-16 | 国立大学法人金沢大学 | アルツハイマー病の診断方法 |
US7479550B2 (en) | 2006-06-02 | 2009-01-20 | The Board Of Regents Of The University Of Texas System | Amyloid β gene vaccines |
US7427342B2 (en) | 2006-06-02 | 2008-09-23 | General Electric Company | Method and apparatus for shifting current distribution in electrodeionization systems |
US20090264359A1 (en) | 2006-06-16 | 2009-10-22 | Cornelis Petrus Maria Van Kessel | Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
EP2043687A4 (de) | 2006-06-29 | 2010-03-17 | Centocor Ortho Biotech Inc | Antiamyloide antikörper, zusammensetzungen, verfahren und verwendungen |
KR20090026275A (ko) | 2006-07-06 | 2009-03-12 | 로스캄프 리서치 엘엘씨 | 베타-아밀로이드 생성을 억제하기 위한 화합물 및 그의 조합물, 및 그의 사용 방법 |
GB2454837A (en) | 2006-07-13 | 2009-05-27 | Parker Hannifin Corp | Emi absorbing gap filling material |
WO2008008463A2 (en) | 2006-07-14 | 2008-01-17 | Trustees Of Columbia University In The City Of New York | METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ |
PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
ES2323725T3 (es) | 2006-07-28 | 2009-07-23 | Vista Ventures Gmbh | Procedimiento para la deteccion de oligomeros de amiloide beta en fluidos corporales. |
US7705475B2 (en) | 2006-08-03 | 2010-04-27 | Stats Chippac Ltd. | Integrated circuit package system |
SG173405A1 (en) | 2006-08-04 | 2011-08-29 | Lonza Biologics Plc | Method for predicting protein aggregation and designing aggregation inhibitors |
US20090123488A1 (en) | 2006-08-14 | 2009-05-14 | Thymon, Llc | Compositions and methods for the treatment and prophylaxis of Alzheimer's disease |
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
WO2008051326A2 (en) | 2006-08-21 | 2008-05-02 | President And Fellows Of Harvard College | Identification of contactins and l1- cams as ligands for the amyloid precursor protein |
WO2008070229A2 (en) | 2006-08-28 | 2008-06-12 | Case Western Reserve University | Detection of pathogenic aggregates of protein in a sample by homologous elisa |
US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
WO2008027526A1 (en) | 2006-08-31 | 2008-03-06 | Biogen Idec Ma Inc. | Methods relating to peripheral administration of nogo receptor polypeptides |
CA2662863A1 (en) | 2006-09-06 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of protein folding disorders |
US20100093001A1 (en) | 2006-09-08 | 2010-04-15 | Frederic Rousseau | Means and methods for the production of amyloid oligomers |
WO2008030251A1 (en) | 2006-09-08 | 2008-03-13 | Georgetown University | Deglycosylated anti-amyloid beta antibodies |
ES2307396B1 (es) | 2006-09-14 | 2009-09-30 | Fundacion Para Investigaciones Neurologicas (Fin) | Sistemas de eliminacion de sustancias neurotoxicas causantes de enfermedades neurodegenerativas mediante su atrapamiento selectivo por inmunoafinidad en el liquido cefalo-raquideo circulante. |
US7375190B2 (en) | 2006-09-19 | 2008-05-20 | National Yang-Ming University | Recombinant protein and method of screening for agents that modulate polypeptide aggregation |
ES2640095T3 (es) | 2006-10-02 | 2017-10-31 | Ac Immune S.A. | Anticuerpo humanizado contra beta-amiloide |
US20100104577A1 (en) | 2006-10-10 | 2010-04-29 | Golde Todd E | Methods and materials related to anti-a (beta) antibodies |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
JP5153114B2 (ja) | 2006-10-12 | 2013-02-27 | 知宏 千葉 | 新規のアルツハイマー病検出方法 |
US20080113444A1 (en) | 2006-10-17 | 2008-05-15 | Pray Todd R | Method for detecting oligermization of soluble amyloid beta oligomers |
GB0620735D0 (en) | 2006-10-18 | 2006-11-29 | Ares Trading Sa | Proteins |
KR100883132B1 (ko) | 2006-10-24 | 2009-02-10 | 재단법인서울대학교산학협력재단 | 아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제 |
WO2008057240A2 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
WO2008130449A2 (en) | 2006-11-20 | 2008-10-30 | Satori Pharmaceuticals, Inc. | Modulators of amyloid-beta production |
WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
WO2008061795A2 (en) | 2006-11-24 | 2008-05-29 | Ac Immune Sa | N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2094730A4 (de) | 2006-12-07 | 2010-08-04 | Mayo Foundation | Verfahren und materialien in zusammenhang mit anti-amyloid-antikörpern |
EP2094729A1 (de) | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Parenterale abeta-antikörper-formulierung |
US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
WO2008084402A2 (en) | 2007-01-11 | 2008-07-17 | Philipps-Universitaet Marburg | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
KR100806914B1 (ko) | 2007-02-14 | 2008-02-22 | 경북대학교 산학협력단 | 퇴행성 신경질환의 예방 및 치료를 위한 리포칼린 2의 신규한 용도 |
WO2008104385A1 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
GB0704394D0 (en) | 2007-03-07 | 2007-04-11 | Senexis Ltd | Compounds |
US20090022728A1 (en) | 2007-03-09 | 2009-01-22 | Rinat Neuroscience Corporation | Methods of treating ophthalmic diseases |
EP1978035A1 (de) | 2007-04-05 | 2008-10-08 | Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung | Antiamyloid-Antikörper und ihre Verwendung bei der Diagnose und Behandlung von amyloidbedingten Erkrankungen |
US20100168250A1 (en) | 2007-04-12 | 2010-07-01 | Antonio Cruz | Use of cyclohexanehexol derivatives in the treatment of ocular disease |
CN101970000A (zh) | 2007-04-18 | 2011-02-09 | 杨森阿尔茨海默氏症免疫治疗公司 | 脑淀粉样血管病的预防和治疗 |
US20100204309A1 (en) | 2007-04-19 | 2010-08-12 | Vib Vzw | Oligonucleotide compositions for the treatment of alzheimer's disease |
WO2008134034A1 (en) | 2007-04-26 | 2008-11-06 | Yale University | Prion protein as a receptor for amyloid-beta oligomers |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
US20100178658A1 (en) | 2007-05-30 | 2010-07-15 | The Regents Of The University Of Michigan | Screening assays for inhibitors of beta amyloid peptide ion channel formation |
US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
CA2690434C (en) | 2007-06-12 | 2018-05-22 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
AU2008267038B2 (en) | 2007-06-12 | 2014-08-07 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
EP2009445A1 (de) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen |
CN101084909A (zh) | 2007-07-03 | 2007-12-12 | 福建医科大学附属协和医院 | 人参皂苷Rg1的新用途 |
WO2009009768A2 (en) | 2007-07-12 | 2009-01-15 | Acumen Pharmaceuticals, Inc. | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS |
US8962677B2 (en) | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
WO2009008890A1 (en) | 2007-07-12 | 2009-01-15 | Acumen Pharmaceuticals, Inc. | METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS |
MX2010000369A (es) | 2007-07-12 | 2010-07-02 | Acumen Pharmaceuticals Inc | Metodos para mejorar la funcion cognitiva usando compuestos no peptidicos. |
GB0719559D0 (en) | 2007-10-05 | 2007-11-14 | Senexis Ltd | Compounds |
SI2238166T1 (sl) | 2007-10-05 | 2014-03-31 | Genentech, Inc. | Uporaba protitelesa proti amiloidu beta pri očesnih bolezni |
CA2701788C (en) | 2007-10-05 | 2017-06-13 | Genentech, Inc. | Humanized beta-amyloid antibody for treating ocular diseases |
SG178809A1 (en) | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
CN101152576A (zh) | 2007-10-15 | 2008-04-02 | 王延江 | 防治阿尔茨海默病的药物 |
WO2010010469A2 (en) | 2008-07-25 | 2010-01-28 | Abbott Gmbh & Co. Kg | Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof |
CN102203124A (zh) | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物,其寡聚物,用于制备的方法以及包括所述类似物或寡聚物的组合物,及其用途 |
PL2401300T3 (pl) | 2009-02-25 | 2018-07-31 | Academia Sinica | Przeciwciała anty-C[epsilon]mX zdolne do wiązania z ludzkim mIgE na limfocytach B |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
-
2003
- 2003-01-31 DE DE10303974A patent/DE10303974A1/de not_active Withdrawn
-
2004
- 2004-02-02 JP JP2006501701A patent/JP5150097B2/ja not_active Expired - Lifetime
- 2004-02-02 CN CN200480008812A patent/CN100595210C/zh not_active Expired - Lifetime
- 2004-02-02 BR BR0407084-4A patent/BRPI0407084A/pt not_active IP Right Cessation
- 2004-02-02 KR KR1020127003623A patent/KR20120042959A/ko not_active Application Discontinuation
- 2004-02-02 NZ NZ541453A patent/NZ541453A/en unknown
- 2004-02-02 EP EP10179281.0A patent/EP2336161B1/de not_active Expired - Lifetime
- 2004-02-02 NZ NZ563779A patent/NZ563779A/en unknown
- 2004-02-02 KR KR1020097000681A patent/KR20090019911A/ko active Search and Examination
- 2004-02-02 CN CN201010004774.3A patent/CN101830974B/zh not_active Expired - Lifetime
- 2004-02-02 KR KR1020057014117A patent/KR20050103483A/ko active IP Right Grant
- 2004-02-02 US US10/543,841 patent/US7902328B2/en active Active
- 2004-02-02 ES ES04707201.2T patent/ES2567437T3/es not_active Expired - Lifetime
- 2004-02-02 MX MXPA05007964A patent/MXPA05007964A/es active IP Right Grant
- 2004-02-02 EP EP10179255A patent/EP2336160A3/de not_active Withdrawn
- 2004-02-02 AU AU2004207075A patent/AU2004207075B2/en not_active Expired
- 2004-02-02 CA CA3000519A patent/CA3000519A1/en not_active Abandoned
- 2004-02-02 EP EP04707201.2A patent/EP1594891B1/de not_active Expired - Lifetime
- 2004-02-02 EP EP10179297A patent/EP2336159A3/de not_active Withdrawn
- 2004-02-02 CA CA2514582A patent/CA2514582C/en not_active Expired - Lifetime
- 2004-02-02 CN CN201010003325.7A patent/CN101985036B/zh not_active Expired - Lifetime
- 2004-02-02 WO PCT/EP2004/000927 patent/WO2004067561A1/de active Application Filing
-
2005
- 2005-08-30 ZA ZA200506934A patent/ZA200506934B/xx unknown
-
2009
- 2009-02-26 IL IL197312A patent/IL197312A0/en unknown
- 2009-09-14 US US12/559,255 patent/US20100209346A1/en not_active Abandoned
-
2010
- 2010-02-02 JP JP2010021337A patent/JP5448890B2/ja not_active Expired - Lifetime
- 2010-04-29 IL IL205430A patent/IL205430A0/en unknown
- 2010-12-22 AU AU2010257323A patent/AU2010257323B8/en not_active Expired
-
2011
- 2011-05-19 IL IL212997A patent/IL212997A0/en unknown
- 2011-08-01 US US13/195,533 patent/US9176150B2/en not_active Expired - Lifetime
-
2012
- 2012-07-09 JP JP2012153998A patent/JP2012250981A/ja active Pending
-
2013
- 2013-10-03 JP JP2013207888A patent/JP2014005295A/ja active Pending
-
2015
- 2015-09-24 US US14/864,526 patent/US10464976B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
WO2001010900A2 (en) * | 1999-08-04 | 2001-02-15 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
Non-Patent Citations (8)
Title |
---|
BITAN GAL ET AL: "Amyloid beta-protein (Abeta) assembly: Abeta40 and Abeta42 oligomerize through distinct pathways.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 100, no. 1, 7 January 2003 (2003-01-07), January 7, 2003, pages 330 - 335, XP002281313, ISSN: 0027-8424 (ISSN print) * |
DAHLGREN KARIE N ET AL: "Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 35, 30 August 2002 (2002-08-30), pages 32046 - 32053, XP002281311, ISSN: 0021-9258 * |
DEMEESTER N ET AL: "Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch N-terminally truncated amyloid beta peptides", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 13, no. 11, June 2001 (2001-06-01), pages 2015 - 2024, XP002281312, ISSN: 0953-816X * |
MCLAURIN J ET AL: "Review: Modulating factors in amyloid-beta fibril formation", JOURNAL OF STRUCTURAL BIOLOGY, vol. 130, no. 2-3, June 2000 (2000-06-01), pages 259 - 270, XP002281315, ISSN: 1047-8477 * |
ROHER^A A E ET AL: "Oligomerization and fibril assembly of the amyloid-beta protein", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, AMSTERDAM, NL, vol. 1502, no. 1, 26 July 2000 (2000-07-26), pages 31 - 43, XP004276971, ISSN: 0925-4439 * |
STINE W BLAINE JR ET AL: "In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 13, 28 March 2003 (2003-03-28), pages 11612 - 11622, XP002281314, ISSN: 0021-9258 * |
WILSON D M ET AL: "FREE FATTY ACIDS STIMULATE THE POLYMERIZATION OF TAU AND AMYLOID BETA PEPTIDES IN VITRO EVIDENCE FOR A COMMON EFFECTOR OF PATHOGENESIS IN ALZHEIMER'S DISEASE", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 150, no. 6, 6 June 1997 (1997-06-06), pages 2181 - 2195, XP000952986, ISSN: 0002-9440 * |
WURTH C ET AL: "Mutations that Reduce Aggregation of the Alzheimer's Abeta42 Peptide: an Unbiased Search for the Sequence Determinants of Abeta Amyloidogenesis", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 5, 21 June 2002 (2002-06-21), pages 1279 - 1290, XP004449702, ISSN: 0022-2836 * |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US8809010B2 (en) | 2003-05-05 | 2014-08-19 | Probiodrug Ag | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases |
US8250823B2 (en) | 2003-08-26 | 2012-08-28 | Ejot Gmbh & Co. Kg | Dowels and methods for the assembly of insulating panels |
US7807165B2 (en) | 2004-07-30 | 2010-10-05 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
US7927594B2 (en) | 2004-07-30 | 2011-04-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide |
US8268593B2 (en) | 2004-07-30 | 2012-09-18 | Rinat Neuroscience Corp. | Polynucleotides encoding antibodies directed against amyloid-beta peptide |
US8168188B1 (en) | 2004-08-11 | 2012-05-01 | Kyoto University | Antibody and utilization of the same |
WO2006094724A2 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
JP2008531635A (ja) * | 2005-03-05 | 2008-08-14 | アボット ゲーエムベーハー ウント カンパニー カーゲー | スクリーニング方法、非拡散性aベータオリゴマーの精製方法、前記非拡散性aベータオリゴマーに対する選択的抗体および前記抗体の製造方法 |
AU2006222193B2 (en) * | 2005-03-05 | 2011-11-17 | AbbVie Deutschland GmbH & Co. KG | Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies |
WO2006094724A3 (en) * | 2005-03-05 | 2007-02-15 | Abbott Gmbh & Co Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
EP2204381A1 (de) | 2005-03-05 | 2010-07-07 | Abbott GmbH & Co. KG | Screeningverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannte nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern |
US8129389B2 (en) | 2005-03-24 | 2012-03-06 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing the latter and use thereof |
US7763250B2 (en) | 2005-04-29 | 2010-07-27 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and nucleic acids encoding same |
US8398978B2 (en) | 2005-04-29 | 2013-03-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2007005359A1 (en) * | 2005-06-30 | 2007-01-11 | Merck & Co., Inc. | Composition and method for producing stable amyloid beta oligomers of high molecular weight |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
CN106008712A (zh) * | 2005-11-30 | 2016-10-12 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
JP2009519012A (ja) * | 2005-11-30 | 2009-05-14 | アボット・ラボラトリーズ | アミロイドベータタンパク質に対するモノクローナル抗体及びその使用 |
WO2007064972A2 (en) * | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
EP2289909A1 (de) | 2005-11-30 | 2011-03-02 | Abbott Laboratories | Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
JP2016183160A (ja) * | 2005-11-30 | 2016-10-20 | アッヴィ・インコーポレイテッド | 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
WO2007062852A3 (en) * | 2005-11-30 | 2007-07-26 | Abbott Lab | ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES |
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
CN105924521A (zh) * | 2005-11-30 | 2016-09-07 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
CN102898519A (zh) * | 2005-11-30 | 2013-01-30 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
CN101506236B (zh) * | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
JP2014040453A (ja) * | 2005-11-30 | 2014-03-06 | Abbvie Inc | 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
JP2014037413A (ja) * | 2005-11-30 | 2014-02-27 | Abbvie Inc | アミロイドベータタンパク質に対するモノクローナル抗体及びその使用 |
JP2009518010A (ja) * | 2005-11-30 | 2009-05-07 | アボット・ラボラトリーズ | ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用 |
JP2009517057A (ja) * | 2005-11-30 | 2009-04-30 | アボット・ラボラトリーズ | 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
CN102898519B (zh) * | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
WO2007062852A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES |
WO2007064972A3 (en) * | 2005-11-30 | 2007-11-01 | Abbott Lab | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US8263558B2 (en) | 2005-11-30 | 2012-09-11 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
US8796439B2 (en) | 2006-07-14 | 2014-08-05 | Ac Immune S.A. | Nucleic acid molecules encoding a humanized antibody |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
EP2097104A2 (de) * | 2006-11-30 | 2009-09-09 | Abbott Laboratories | Neue monoklonale a-beta-konformer-selektive anti-a-beta-globulomer-antikörper |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
EP2097104A4 (de) * | 2006-11-30 | 2010-06-02 | Abbott Lab | Neue monoklonale a-beta-konformer-selektive anti-a-beta-globulomer-antikörper |
US7939075B2 (en) | 2007-01-11 | 2011-05-10 | Philipps-Universitaet Marburg | Human monoclonal anti-amyloid-beta antibodies |
US8491903B2 (en) | 2007-01-11 | 2013-07-23 | Philipps-Universitaet Marburg | Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
WO2008104385A1 (en) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
EP2486928A1 (de) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Verfahren zur Behandlung von Amyloidosen |
EP2481408A2 (de) | 2007-03-01 | 2012-08-01 | Probiodrug AG | Neue Verwendung von Inhibitoren der Glutaminyl Cyclase |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2865670A1 (de) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thioharnstoffderivative als Glutaminylcyclaseinhibitoren |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9585956B2 (en) | 2007-06-12 | 2017-03-07 | Ac Immune S.A. | Polynucleotides encoding anti-amyloid beta monoclonal antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
US9605069B2 (en) | 2008-02-29 | 2017-03-28 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM a protein and uses thereof |
US10138281B2 (en) | 2008-04-14 | 2018-11-27 | Alzinova Ab | Stable amyloid beta monomers and oligomers |
US9688734B2 (en) | 2008-04-14 | 2017-06-27 | Alzinova Ab | Stable amyloid beta monomers and oligomers |
US10023622B2 (en) | 2008-04-14 | 2018-07-17 | Alzinova Ab | Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers |
WO2010010469A2 (en) * | 2008-07-25 | 2010-01-28 | Abbott Gmbh & Co. Kg | Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof |
WO2010010469A3 (en) * | 2008-07-25 | 2010-03-18 | Abbott Gmbh & Co. Kg | Amyloid beta (x - 38.. 43) oligomers, and processes, compositions, and uses thereof |
US8283162B2 (en) | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
WO2010104815A1 (en) | 2009-03-10 | 2010-09-16 | Abbott Laboratories | Antibodies binding to pivka-ii amino acids 13-27 |
US9011862B2 (en) | 2009-07-11 | 2015-04-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitors of the nitration of amyloid β peptides and their uses in the diagnosis and treatment of Alzheimer's disease |
WO2011006871A1 (en) * | 2009-07-11 | 2011-01-20 | Rheinische Friedrich-Wilhelms-Universität Bonn | INHIBITORS OF THE NITRATION OF AMYLOID ß PEPTIDES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE |
EP2273273A1 (de) * | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer |
US8501420B2 (en) | 2009-08-31 | 2013-08-06 | Abbott Laboratories | Biomarkers for prediction of major adverse cardiac events and uses thereof |
WO2011026017A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Laboratories | Biomarkers for prediction of major adverse cardiac events and uses thereof |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
WO2012018476A1 (en) | 2010-07-26 | 2012-02-09 | Abbott Laboratories | Antibodies relating to pivka-ii and uses thereof |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
EP3533803A1 (de) | 2010-08-14 | 2019-09-04 | AbbVie Inc. | Amyloid-beta-bindende antikörper |
US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US10106602B2 (en) | 2012-01-27 | 2018-10-23 | AbbVie Deutschland GmbH & Co. KG | Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof |
US9365643B2 (en) | 2012-01-27 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Antibodies that bind to repulsive guidance molecule A (RGMA) |
US9102722B2 (en) | 2012-01-27 | 2015-08-11 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
EP3498692A1 (de) | 2014-01-31 | 2019-06-19 | Cognition Therapeutics, Inc. | Isoindolinzusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen |
WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
EP4023294A1 (de) | 2014-01-31 | 2022-07-06 | Cognition Therapeutics, Inc. | Isoindolinzusammensetzungen und verfahren zur behandlung der alzheimer-krankheit |
EP3461819A1 (de) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Hemmer der glutaminylcyclase |
WO2019121263A1 (de) * | 2017-12-18 | 2019-06-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Verfahren zur auftrennung verschiedener abeta-peptide durch gelelektrophorese |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2336161B1 (de) | Amyloid-beta(1-42)-Oligomere, Derivate davon und Antikörper dafür, Verfahren zu deren Herstellung und deren Verwendung | |
DK1954718T3 (en) | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, | |
DE60032486T2 (de) | Prion protein peptide und deren verwendung | |
EP1928905B1 (de) | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung | |
DK2289909T3 (en) | The screening method, method of purification of non-diffusing alpha-beta oligomers selective antibodies to said non-diffunderingsdygtige alpha-beta oligomers and a method of producing said antibodies | |
WO2006077101A2 (de) | Ager-peptide und deren verwendung | |
DE102005002353A1 (de) | AGER-Rezeptor Multimerisierungs Epitope | |
DE102005015832A1 (de) | AGER-Rezeptor Multimerisierungs Epitope |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 541453 Country of ref document: NZ Ref document number: 169888 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2514582 Country of ref document: CA Ref document number: PA/a/2005/007964 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1728/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006501701 Country of ref document: JP Ref document number: 1020057014117 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004207075 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004207075 Country of ref document: AU Date of ref document: 20040202 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004207075 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004707201 Country of ref document: EP Ref document number: 2005/06934 Country of ref document: ZA Ref document number: 200506934 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048088125 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057014117 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004707201 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407084 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007098721 Country of ref document: US Ref document number: 10543841 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10543841 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 197312 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205430 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212997 Country of ref document: IL |